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 i 
Abstract 
Dog’s treated for hypoadrenocorticism are routinely monitored through analysis of their 
blood electrolyte concentrations. This is often performed with point-of-care analysers to 
facilitate faster medication dose adjustments based on the results.   
The objective of this study was to investigate the performance of two point-of-care 
analysers (IDEXX Catalyst™ Dx and IDEXX VetStat®) against a reference laboratory 
indirect ion-selective-electrode method (Olympus AU640 or Siemens Dimenson Xpand 
Plus) for the measurement of blood sodium, potassium and chloride concentrations, as 
well as the sodium: potassium ratio, in dogs diagnosed with and treated for 
hypoadrenocorticism. 
Forty-eight dogs were enrolled into a prospective cross-sectional study. Paired blood 
samples were taken and tested on the two point-of-care analysers and at the reference 
laboratory. Statistical analysis was then performed with Spearman’s correlations, Bland-
Altman analysis, Passing-Bablok regression and Cohen’s Kappa analysis. The clinical 
effects of inaccurate electrolyte analysis were also considered.  
In total, 329 samples were tested on the IDEXX Catalyst™ Dx analyser, whilst another 
72 samples were tested on the IDEXX VetStat®. Spearman’s correlations were 
acceptable for all electrolytes, but regression analysis identified both proportional and 
constant bias for some analytes. There was poor agreement between sodium and chloride 
concentrations on both analysers and they tended to give higher results than the reference 
ISE method for all analytes, except for potassium when measured on the IDEXX 
VetStat®.  
In conclusion, there are inherent differences between the electrolyte concentrations 
measured by these two point-of-care analysers and reference laboratory methods in dogs 
with hypoadrenocorticism. Clinicians should be aware of this and consistent in their 
method of measurement of electrolytes when monitoring these dogs  
 
 
Key words: canine, dogs, hypoadrenocorticism, Addison’s disease, fludrocortisone, 
desoxycortone pivalate, DOCP, electrolytes, sodium, potassium, chloride, Olympus 
AU640, Siemens Dimension Xpand Plus, Idexx Catalyst™ Dx, Idexx VetStat® 
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1 Introduction 
1.1 Hypoadrenocorticism 
Hypoadrenocorticism (HA), also known as Addison’s disease, is a well-described 
endocrinopathy in dogs characterised by a lack of adrenocortical function resulting in 
inadequate secretion of both mineralocorticoids (aldosterone) and glucocorticoids 
(cortisol). The anatomy and physiology of the adrenal glands is described in detail 
elsewhere (Dyce et al., 2017). The development of clinical signs is believed to require 
destruction of at least 90% of the adrenal cortex (Scott-Moncrieff, 2015). 
1.1.1 Glucocorticoids 
The major glucocorticoid is cortisol which is synthesised from cholesterol and secreted 
via a complex process involving multiple enzymes. Cortisol levels are regulated by the 
hypothalamic-pituitary-adrenal (HPA) axis via corticotrophin-releasing hormone (CRH) 
which is released from the hypothalamus and stimulates secretion of adrenocorticotrophic 
hormone (ACTH) from the anterior pituitary gland. ACTH is released into the 
bloodstream and stimulates the adrenal gland cortex (zona fasciculata (ZF) and zona 
reticularis (ZR)) to produce cortisol. CRH release is triggered by pain, stress 
hypoglycaemia and physical exercise. As cortisol levels rise, CRH and ACTH release is 
inhibited via negative feedback and increased levels of ACTH also inhibit CRH release 
itself (Klein, 2013, Scott-Moncrieff, 2015). ACTH levels in humans fluctuate with 
circadian rhythms however this is not the case in the dog. In addition to CRH, ACTH 
release can also be stimulated by arginine vasopressin (AGP), angiotensin II, 
cholecystokinin (CCK), atrial natriuretic factor (ANP) and vasoactive peptides (Stewart 
and Krone, 2011).  
Cortisol affects almost every tissue and is crucial to maintaining homeostasis. It is 
involved in the metabolism of sugars, fats and protein, improves the body’s defence 
against long term stress by suppressing the immune system, reduces the release of 
inflammatory mediators and maintains the gastrointestinal mucosa (Peterson et al., 1996, 
Langlais-Burgess et al., 1995). Cortisol also helps to regulate blood pressure, water 
balance and vascular volume by increasing water diuresis, glomerular filtration rate and 
renal plasma flow from the kidneys. Cortisol binds to mineralocorticoid receptors but has 
only weak mineralocorticoid activity (Rose and Post, 2017). 
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1.1.2 Mineralocorticoids 
The major mineralocorticoid is aldosterone. The zona glomerulosa (ZG) is the only layer 
of the adrenal cortex capable of secreting aldosterone as it contains the enzyme 
aldosterone synthase (P450 c11AS). Additionally it does not contain 17-alpha-
hydroxylase (P450 c17) and as such, cannot synthesise cortisol (Scott-Moncrieff, 2015). 
Unlike the glucocorticoids, tropic hormones from the pituitary gland do not control 
mineralocorticoid release, instead aldosterone synthesis and secretion is controlled 
primarily by the renin-angiotensin system (RAS) and plasma potassium concentration 
and to a lesser extent by plasma sodium and ACTH concentrations (Klein, 2013). 
Angiotensin synthesis is stimulated by decreased extracellular fluid (ECF) volume and 
causes renin to be released from the juxtaglomerular cells in the kidney. Renin acts to 
convert angiotensinogen to angiotensin I which is in turn converted to angiotensin II 
primarily in the lungs by angiotensin converting enzyme (ACE). Angiotensin II 
stimulates increased aldosterone synthesis. Increased plasma potassium acts directly on 
the adrenal gland to promote aldosterone release (Scott-Moncrieff, 2015). An absence of 
ACTH decreases aldosterone secretion but does not prevent aldosterone secretion 
altogether as evidenced by normal mineralocorticoid levels in dogs post hypophysectomy 
(Meij et al., 1997). 
Aldosterone promotes distal renal tubular reabsorption of sodium and chloride and 
facilitates the secretion of potassium and hydrogen ions via the kidney, sweat and salivary 
glands and the intestinal tract. As such a lack of aldosterone leads to hyponatraemia and 
hyperkalaemia, is critical in conserving body salts and can cause a mild metabolic 
acidosis (Scott-Moncrieff, 2015).  Aldosterone release is inhibited by dopamine and ANP, 
which are released in response to volume expansion (DiBartola, 2012). 
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1.2 Aetiology of Hypoadrenocorticism  
1.2.1.1 Primary Hypoadrenocorticism 
1.2.1.1.1 Naturally Occurring Primary Hypoadrenocorticism  
Naturally occurring primary hypoadrenocorticism results from atrophy or destruction of 
all three adrenal cortical layers. Primary immune-mediated destruction is thought to be 
the main cause and anti-adrenal antibodies have been detected in dogs (Schaer et al., 
1986). Histological evaluation of the adrenal glands of dogs with primary 
hypoadrenocorticism typically shows lymphoplasmacytic inflammation (Frank et al., 
2013). However, in most dogs a definitive cause is never proven, and their disease is 
considered idiopathic. Rare cases of adrenal cortex destruction with different aetiologies 
have also been reported such as infiltrative fungal or granulomatous disease, neoplasia, 
amyloidosis, infarction, haemorrhage due to trauma or coagulopathy, or iatrogenic causes 
(Labelle and De Cock, 2005, Kook et al., 2010, Korth et al., 2008, Rockwell et al., 2005, 
Reusch et al., 2007, Frank et al., 2013, Scott-Moncrieff, 2015).  
1.2.1.1.2 Iatrogenic Primary Hypoadrenocorticism 
Iatrogenic primary hypoadrenocorticism can result from drugs that cause destruction of 
the adrenal cortices. Mitotane (Lysodren) is directly cytotoxic to the adrenal gland and 
dogs may develop adrenocortical insufficiency during treatment for 
hyperadrenocorticism (HAC). This is usually transient however up to 5% of dogs may 
develop permanent hypoadrenocorticism (Kintzer and Peterson, 1991, den Hertog et al., 
1999). Trilostane (Vetoryl) may cause adrenal suppression which is usually reversible but 
permanent hypoadrenocorticism has been reported associated with adrenal necrosis and 
haemorrhage (Reusch et al., 2007, Chapman et al., 2004, Reine, 2007, Braddock et al., 
2003, Alenza et al., 2006, Neiger et al., 2002).  
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1.2.1.1.3 Atypical Primary Hypoadrenocorticism 
Atypical hypoadrenocorticism represents <10% of cases. Affected dogs have normal 
electrolytes at diagnosis and are thought to have ZG sparing and therefore maintenance 
of normal aldosterone levels (Kintzer and Peterson, 1997a, Klein and Peterson, 2010a, 
Frank et al., 2013). However, some dogs with low aldosterone concentrations have also 
been found to have normal electrolyte concentrations implying that the maintenance of 
normal levels is not solely aldosterone dependent and there are other mechanisms by 
which dogs maintain normal electrolyte status (Baumstark et al., 2014b). It may be that 
the loss of adrenocortical tissue affecting the ZF and ZR occurs prior to or at a faster rate 
than the loss of the ZG and these patients may develop electrolyte abnormalities in time 
as their disease progresses (Klein and Peterson, 2010a, Scott-Moncrieff, 2015).  
1.2.1.2 Secondary Hypoadrenocorticism  
Iatrogenic secondary hypoadrenocorticism is much more common than naturally 
occurring disease. Typically, it is due to chronic administration and sudden withdrawal 
of exogenous glucocorticoids which suppress ACTH release from the anterior pituitary 
causing atrophy of the ZF and ZR. Alternatively iatrogenic disease may occur after 
hypophysectomy (Scott-Moncrieff, 2015).  
Naturally occurring secondary hypoadrenocorticism is rarely reported and results from a 
failure of the pituitary gland to secrete ACTH or decreased CRH secretion by the 
hypothalamus (Kintzer and Peterson, 1997a). This may be due to destruction of the 
pituitary gland by neoplasia, inflammation, infection, infarction or head trauma and can 
cause acute neurological dysfunction and death (Platt et al., 1999, Foley et al., 2009, 
Eckersley et al., 1989, Scott-Moncrieff, 2015, Bertolini et al., 2007). Lack of ACTH 
causes severe atrophy of the ZF and ZR but leaves the ZG intact. As such serum 
electrolytes remain normal as aldosterone secretion is not affected resulting in a pure 
glucocorticoid deficiency. Unlike atypical primary hypoadrenocorticism, ACTH 
concentrations are low (Hess, 2017). Among all dogs with hypoadrenocorticism, the 
incidence of secondary hypoadrenocorticism is estimated between 4% and 24% (Klein 
and Peterson, 2010a). 
1.2.1.3 Tertiary Hypoadrenocorticism  
Tertiary hypoadrenocorticism is caused by hypothalamic disorders disrupting CRH 
secretion resulting in decreased ACTH production and is very rarely reported in humans 
and has never been reported in dogs (Klein and Peterson, 2010a).   
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1.3 Investigation of Hypoadrenocorticism 
1.3.1 Historical and Clinical Signs of Hypoadrenocorticism 
1.3.1.1 Signalment 
Hypoadrenocorticism can affect dogs of any age, breed or sex however there are strong 
breed predispositions. Affected animals tend to be young to middle-aged with a median 
age at diagnosis of 4 years and a reported range of 2 months to 16 years (Peterson et al., 
1996, Seth et al., 2011, Adler et al., 2007, Klein and Peterson, 2010a). 
Hypoadrenocorticism has been estimated to have a prevalence of up to 0.28% (Kelch et 
al., 1998) in the overall canine population. Any breed may be affected but certain breeds 
are at an increased risk for developing the disease. It is an autosomal recessive trait in the 
Standard Poodle (Famula et al., 2003), Portuguese Water Dog (Oberbauer et al., 2006) 
and Nova Scotia Duck Tolling Retriever (Hughes et al., 2007). In Bearded Collies, 
hypoadrenocorticism is a highly heritable trait but the exact mechanism of inheritance is 
unclear (Oberbauer et al., 2002). Females tend to be overrepresented, accounting for 
around 70% of cases however in these four breeds the female predisposition is not seen 
(Scott-Moncrieff, 2015). Nova Scotia Duck Tolling Retrievers also seem to have an 
earlier onset of disease compared to other breeds with an average age of 2.6 years (Hughes 
et al., 2007). Other breeds which are overrepresented include Great Danes, West Highland 
White Terriers, Springer Spaniels, Soft-Coated Wheaten Terriers and Basset Hounds 
(Klein and Peterson, 2010a, Thompson et al., 2007). Golden Retrievers, Yorkshire 
Terriers, Pit Bulls, Chihuahuas and Lhasa Apso’s have decreased risk (Peterson et al., 
1996). 
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1.3.1.2 History and Clinical Signs 
The onset of clinical signs can be gradual and may initially be missed by owners although 
in other cases a stressful event can precipitate illness. A history of episodic disease which 
responds to supportive care is suspicious for hypoadrenocorticism. Dogs with 
hypoadrenocorticism may exhibit a range of clinical signs, many of which are vague and 
non-specific and can be attributed to multiple body systems and differential diagnoses. 
Common clinical signs include anorexia, weight loss, vomiting, diarrhoea, lethargy, 
weakness and shaking/shivering. Polyuria (PU), polydipsia (PD) and abdominal pain may 
be observed and in more extreme cases affected dogs may have gastrointestinal 
haemorrhage, collapse or they may seizure due to hypoglycaemia. Glucocorticoid 
deficiencies may account for most of these signs due to their role in maintaining the 
gastrointestinal mucosa, blood pressure and fluid volume, body temperature and glucose 
levels. However when mineralocorticoid deficiencies are also present clinical signs such 
as PU/PD, hypovolemic shock, collapse and dehydration tend to be more severe (Greco, 
2007, Peterson et al., 1996, Klein and Peterson, 2010a, Feldman et al., 2015) 
1.3.1.3 Clinical examination 
Physical examination is often normal especially in chronic cases and any abnormalities 
maybe vague and nonspecific. When abnormalities are present, they can range from mild 
dehydration to hypovolaemic shock and collapse with prolonged capillary refill time 
(CRT) and weak pulses. Most commonly dogs present with weakness, lethargy, 
hypothermia and dehydration. Dogs with hypoadrenocorticism are often in thin body 
condition and occasionally have abdominal pain. Bradycardia in a collapsed or unwell 
dog is suspicious for hyperkalaemia of which hypoadrenocorticism is a differential 
diagnosis (Klein and Peterson, 2010a, Greco, 2007).  
1.3.1.4 Differential diagnosis 
Given the vague and sometime episodic clinical signs which respond quickly to 
symptomatic treatment, HA can be confused for many other disease processes. These 
include intestinal disease (e.g. inflammatory bowel disease (IBD), protein losing 
enteropathy (PLE), parvovirus), kidney disease (e.g. acute kidney injury (AKI), chronic 
kidney disease (CKD)), endocrine disease (e.g. insulinoma, pheochromocytoma) and 
hepatic disease (e.g. chronic hepatopathy). 
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1.3.2 Clinical Pathological Changes Associated with Hypoadrenocorticism  
1.3.2.1 Haematology 
There are several non-specific haematological changes found in dogs with 
hypoadrenocorticism. The “classic” change is a reverse stress leucogram (i.e. low/normal 
neutrophil numbers with increased lymphocytes and eosinophils) but this is not present 
in most cases (Scott-Moncrieff, 2015). More commonly dogs with hypoadrenocorticism 
there is an absence of a stress leucogram in a systemically unwell dog but this is not 
specific enough to confirm a diagnosis (Seth et al., 2011, Zeugswetter and 
Schwendenwein, 2014). This change is due to a lack of cortisol which prevents 
sequestration of lymphocytes in the lymph nodes and bone marrow resulting in normal to 
elevated lymphocyte numbers in the circulation. One study found a lymphocyte count 
>0.75x103/µL had a sensitivity of 100% in dogs with hypoadrenocorticism and a 
specificity of 35% (Seth et al., 2011). An eosinophilia is also not uncommonly found, 
occurring in around 10 to 20% of cases (Greco, 2007, Kintzer and Peterson, 1997a, Klein 
and Peterson, 2010a). Another common finding (21% - 25% of cases) is a normocytic 
normochromic non-regenerative anaemia which is typically mild to moderate (with a 
haematocrit (HCT) of 20%-35%) although this can be more severe. This anaemia is 
attributed to a lack of red cell production due to cortisol deficiency combined with 
gastrointestinal blood loss. Melena or haematochezia is present in up to 15% of dogs 
(Medinger et al., 1993, Peterson et al., 1996). This anaemia may be masked by 
dehydration and some dogs may even appear to have increased an increased packed cell 
volume (PCV) if the dehydration is severe. As with clinical signs, haematological 
findings may be normal. Dogs with glucocorticoid deficient hypoadrenocorticism (i.e. 
with normal electrolytes) are more likely to be anaemic than those with mineralocorticoid 
deficiency alone (Thompson et al., 2007). 
1.3.2.2 Electrolytes and the Sodium: Potassium Ratio 
Electrolyte abnormalities are the most common biochemical finding in dogs with 
hypoadrenocorticism and their measurement is the focus of this MVM thesis. They are 
discussed in greater detail in chapter 1.4.  
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1.3.2.3 Biochemistry 
Most canine patients with hypoadrenocorticism are azotaemic at presentation due to 
hypotension, reduced renal perfusion and hypovolemia due to inadequate reabsorption of 
water from the kidneys. This may be marked and difficult to differentiate from AKI 
(Peterson et al., 1996). This azotaemia tends to resolve quickly with IV fluid therapy 
when treating HA in contrast to AKI. The urea maybe disproportionally more increased 
than creatinine in part due to gastrointestinal haemorrhage due to glucocorticoid 
deficiency and reduced gastrointestinal tract perfusion (Scott-Moncrieff, 2015). 
Around a third of patients may be hypoglycaemic and this may be severe enough to cause 
seizures (Lifton et al., 1996). This is more common in dogs with atypical HA due to 
glucocorticoid deficiency, reduced gluconeogenesis and increased insulin sensitivity 
(Scott-Moncrieff, 2015).  
Another third of patients have increases in their liver enzymes. This may be a combination 
of secondary reaction and hepatic dysfunction. Less commonly dogs may have 
hypoalbuminaemia (6 – 39%) and hypocholesterolaemia (7%). These changes are more 
frequently seen in atypical hypoadrenocorticism and are thought to be due to a 
combination of hepatic dysfunction (albumin and cholesterol), protein losing enteropathy 
(albumin) and altered fat metabolism (cholesterol) (Scott-Moncrieff, 2015).  
Patients may have a mild metabolic acidosis due to reduced hydrogen ion excretion, 
hypovolaemia and hyperlactatemia as a result of poor tissue perfusion (Kintzer and 
Peterson, 1997b). 
1.3.2.4 Urinalysis 
Most dogs with hypoadrenocorticism are hypovolemic at diagnosis with a consequent 
pre-renal azotaemia. However, despite this, their urine specific gravity (USG) is often 
<1.030 as they are unable to conserve water.  
1.3.2.5 Blood Pressure 
Many dogs with hypoadrenocorticism are hypotensive at the time of initial examination 
with a median systolic blood pressure of 90 mmHg (range 40-150 mmHg) versus a 
median of 140 mmHg (range 50-210 mmHg) in dogs with other causes of illness (Seth et 
al., 2011). 
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1.3.2.6 Differential diagnosis 
As with the clinical signs and physical examination findings, laboratory findings can be 
non-specific and confused with other disease processes. The classic electrolyte 
abnormalities of hyponatremia and hyperkalaemia and therefore low Na+: K+ ratios may 
be seen in dogs with gastrointestinal, renal or cardiac disease, urinary obstruction, body 
cavity effusions and diabetes mellitus. This can be compounded in patients with more 
than one concurrent illness. Additionally, gross lipemia and potassium EDTA 
contamination can cause artefactual changes in electrolyte concentrations. 
1.3.3 Diagnostic Imaging 
1.3.3.1 Radiography 
Radiography is indicated to evaluate for other differential diagnoses such as obstructive 
gastrointestinal disease. Common thoracic and abdominal radiographic abnormalities in 
untreated dogs with hypoadrenocorticism are non-specific and secondary to 
hypovolaemia. They include microcardia, microhepatica, narrow caudal vena cava and 
small cranial lobar pulmonary artery (Melian et al., 1999, Peterson et al., 1996). Less 
commonly there may be evidence of megaoesophagus or oesophageal dilation which is 
reversible with treatment (Bartges and Nielson, 1992, Whitley, 1995, Lifton et al., 1996, 
Peterson et al., 1996, Kintzer and Peterson, 1997a). The cause of this is not clear but may 
be due to cortisol deficiency and associated muscle weakness or due to abnormal sodium 
and potassium concentrations affecting membrane potentials and neuromuscular 
function. However, abnormal serum electrolyte concentrations are not always 
documented (Scott-Moncrieff, 2015). 
1.3.3.2 Echocardiography 
Dogs with hypoadrenocorticism are sometimes assessed with echocardiography due to 
bradycardia and concerns about heart function such as hypotension. They may have poor 
systolic function and appear volume underloaded which can be confused for heart disease 
e.g. dilated cardiomyopathy. These changes improve with treatment of the underlying 
hypoadrenocorticism (Spence et al., 2018).  
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1.3.3.3 Abdominal ultrasound 
Most dogs with hypoadrenocorticism have measurably decreased adrenal gland size and 
occasionally they cannot be visualised by ultrasonography. A left adrenal gland thickness 
<3.22 mm is strongly suggestive of HA however the adrenal glands may be normal in 
size (Hoerauf and Reusch, 1999, Wenger et al., 2010). Ultrasonographic examination also 
allows investigation of other differential diagnoses which can all present with similar 
clinical signs. 
1.3.4 Electrocardiography 
Many dogs with hypoadrenocorticism are bradycardic on presentation and therefore may 
be assessed via electrocardiography (ECG). This bradycardia is due to disturbed cardiac 
function as a result of hyperkalaemia which if left untreated can result in ventricular 
fibrillation, standstill and cardiac arrest (Melian and Peterson, 1996). This occurs as a 
result of a decreased ratio between the potassium concentration in the intracellular fluid 
(ICF) and ECF resulting in a decrease in the resting membrane potential. Persistent 
depolarisation inactivates cell surface Na+ channels reducing excitability and thus muscle 
weakness and abnormal cardiac conduction occur (Scott-Moncrieff, 2015). The severity 
of bradycardia is not precisely correlated with serum potassium levels but ECG changes 
generally worsen as the concentration rises (Côté and Ettinger, 2017). Characteristic 
changes consistent with hyperkalaemia are seen on ECG, namely low amplitude or absent 
P waves, spiked T waves, widened QRS complexes and ectopic ventricular beats. ECG 
changes however are not always present or consistent with other factors affecting ECF 
K+ concentrations such as pH, hyponatraemia and the presence of hypercalcaemia which 
may be cardioprotective. Occasionally other less common arrhythmias such as atrial 
fibrillation are seen due to other concurrent electrolyte abnormalities, acidosis and 
myocardial reperfusion injury (Riesen and Lombard, 2006). 
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1.3.5 Confirming the Diagnosis of Hypoadrenocorticism 
1.3.5.1 Basal Cortisol 
Basal (or “resting”) cortisol levels are an excellent screening test to exclude 
hypoadrenocorticism and various cut-off levels have been investigated in the literature. 
Most clinicians currently use a cortisol level >55nmol/L to exclude hypoadrenocorticism 
due to its sensitivity of 100%, however it is only 63 – 78% specific. A lower cut-off of 
28 nmol/L was previously used due to its higher specificity of 92 – 98% but its sensitivity 
may be as low as 86% (Bovens et al., 2014, Lennon et al., 2007). More recently a cut-off 
of 22 nmol/L has been suggested to maximise the sensitivity and specificity at 97 and 
98% respectively (Gold et al., 2016). Cortisol remains stable in serum for up to 5 days 
(Behrend et al., 1998) and in dogs, its release is not affected by the time of day (Scott-
Moncrieff, 2015). Cortisol assays are run on plasma by radioimmunoassay, 
chemiluminescent assay or enzyme-linked immunosorbent assay (Russell et al., 2007). 
1.3.5.2 ACTH Stimulation Test 
The ACTH stimulation test is the recognised standard for confirming a diagnosis of 
hypoadrenocorticism. It involves the measurement of a basal cortisol level, followed by 
an injection of synthetic ACTH, followed by a second cortisol measurement. Various 
different protocols have been examined in the literature comparing the route of 
administration of the synthetic ACTH (intravenous, intramuscular or perivascular) 
(Cohen and Feldman, 2012, Johnson et al., 2017), different doses of synthetic ACTH (0.5 
µg/kg , 5 µg/kg, 250 µg/dog) (Martin et al., 2007, Lathan et al., 2008) and different 
timings for the second post-ACTH cortisol sample (30 to 90 minutes) (Frank et al., 2000). 
These findings have recommended a standard dose of 5 µg/kg synthetic ACTH with a 
second post-ACTH sample taken 60 minutes later. A diagnosis of hypoadrenocorticism 
is made when both the pre and post ACTH cortisol levels are <55nmol/L, with a 
sensitivity and specificity of 100%. The use of the ACTH stimulation test and its 
confounding factors such as exogenous corticosteroid use, are reviewed in more detail 
elsewhere (Scott-Moncrieff, 2015, Klein and Peterson, 2010b, Spence et al., 2018). 
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1.3.5.3 Further Confirmatory Testing 
Further information regarding the use of endogenous ACTH levels, aldosterone 
concentrations, plasma renin activity, aldosterone-to-renin ratio and the cortisol-to-
creatinine ratio are reviewed elsewhere (Javadi et al., 2006, Scott-Moncrieff, 2015, 
Boretti et al., 2015, Lathan et al., 2014, Baumstark et al., 2014b, Thompson et al., 2007, 
Lifton et al., 1996, Baumstark et al., 2014a, Montori and Young, 2002, Boer et al., 1985). 
1.3.6 Treatment of Hypoadrenocorticism 
1.3.6.1 Acute Treatment of Hypoadrenocorticism 
The acute management of hypoadrenocorticism is discussed in more detail elsewhere 
(Scott-Moncrieff, 2015, Spence et al., 2018). Most patients with hypoadrenocorticism 
present acutely due to dehydration, hypovolaemia and hypotension due to 
mineralocorticoid deficiency. Therefore, initial management is directed towards the 
administration of intravenous fluid therapy and management of electrolyte disturbances 
if present. This is one reason why accurate and reproducible results between electrolyte 
analysers is important. Care must be taken not to correct hyponatraemia too quickly due 
to the risk of causing delayed pontine osmotic demyelination and resultant neurological 
signs which can be fatal (O'Brien et al., 1994, Churcher et al., 1999). Hyperkalaemia will 
usually resolve with fluid therapy but often large volumes, so called “shock rates” of 40 
to 80 ml/kg, may be needed. This is usually administered in smaller boluses of 5 to 10 
ml/kg to effect with frequent reassessment of the dogs clinical status (Gunn et al., 2016). 
If hyperkalaemia does not resolve or if the patient is severely bradycardic with ECG 
changes, IV calcium gluconate can be given diluted and administered slowly 
intravenously. This reduces the excitability of the cardiac myocytes and is 
cardioprotective (DiBartola, 2001). The use of neutral insulin and dextrose to move 
potassium intracellularly, is often used to treat hyperkalaemia due to urinary obstruction 
and can be considered in hypoadrenocorticism cases. However, care must be taken not to 
worsen any existing hypoglycaemia (Scott-Moncrieff, 2015).  
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Glucocorticoid (plus or minus mineralocorticoid) supplementation is essential to treat an 
Addisonian crisis however samples for ACTH stimulation and other confirmatory testing 
should ideally be collected prior to administration of any exogenous steroids. This is 
because they can cause HPA axis suppression through negative feedback on the pituitary 
gland, suppressing cortisol release and may also cross react with commercial cortisol 
assays. Hydrocortisone sodium succinate has equal glucocorticoid and mineralocorticoid 
activity and has been shown to achieve faster normalisation of electrolytes and resolution 
of clinical signs other than steroids when administered as a constant rate infusion (0.5 – 
0.625mg/kg/hour) (Gunn et al., 2016).  
1.3.6.2 Chronic Treatment of Hypoadrenocorticism 
All patients with hypoadrenocorticism require glucocorticoid supplementation regardless 
of if they have classical or atypical forms of the disease (Klein and Peterson, 2010b, 
Spence et al., 2018). Mineralocorticoid supplementation however is only required when 
there are electrolyte derangements or inappropriately low endogenous aldosterone levels 
(Baumstark et al., 2014b, Wakayama et al., 2017).  
1.3.6.2.1 Glucocorticoids 
Most patients receive glucocorticoid supplementation in the form of prednisolone given 
once a day. Prednisolone is a pure glucocorticoid so patients requiring mineralocorticoid 
support will require this separately as discussed below (Scott-Moncrieff, 2015). A wide 
range of doses are reported in the literature (<0.05 to 0.4 mg/kg/day) and the dose required 
seems to be vary between individuals (Kintzer and Peterson, 1997b). During 
physiological stress or illness, glucocorticoid requirements may increase by up to 5 fold 
(Klein and Peterson, 2010b). Prednisolone has the side effects of causing polyphagia, PU, 
PD, panting and poor hair growth (Plumb, 2018). 
1.3.6.2.2 Mineralocorticoids 
When necessary, there are two treatments commonly used for chronic aldosterone 
supplementation in dogs. Over and under dosing can cause hypertension and polydipsia, 
depression, lethargy and gastrointestinal signs (Plumb, 2018). 
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1.3.6.2.2.1 Fludrocortisone acetate 
Fludrocortisone acetate is a steroid formulation with both glucocorticoid and 
mineralocorticoid activity and as such, adjunctive prednisolone is often not required 
however it does decrease the time for clinical stabilisation early in treatment (Roberts et 
al., 2016). The use of fludrocortisone is off license in dogs with a recommended starting 
dose of 0.02 mg/kg/day, given as one or two doses (Plumb, 2018), however a wide range 
of doses are reported (0.01 to 0.08 mg/kg/day) (Scott-Moncrieff, 2015, Kintzer and 
Peterson, 1997b, Roberts et al., 2016). 
1.3.6.2.2.2 Desoxycortone pivalate 
Desoxycortone pivalate (DOCP) is a pure mineralocorticoid (McCabe et al., 1995, Lynn 
and Feldman, 1991, Lynn et al., 1993, Van Zyl and Hyman, 1994). Although it may have 
a trivial effect on glucocorticoid receptors, additional glucocorticoid supplementation is 
required (Scott-Moncrieff, 2015). DOCP is the only licensed treatment of 
hypoadrenocorticism in dogs and two 25 mg/ml prolonged-release microcrystalline 
formulations are available; Percorten® (Novartis) in North America and Zycortal® 
(Dechra Ltd) in Europe. These have recently been shown to be non-inferior (Farr et al., 
2020). The starting dose of Zycortal® is 2.2 mg/kg administered subcutaneously every 25 
– 28 days (European Medicines Agency, 2019) although evidence from studies using 
Percorten® suggests that often much lower doses are required long term (Kintzer and 
Peterson, 1997b, Bates et al., 2013). Due to its rapid onset of action, only a brief transition 
period of around 48 hours is needed when changing from fludrocortisone to DOCP (Scott-
Moncrieff, 2015, Ramsey et al., 2016) with peak activity around 10 days after injection 
(Jaffey et al., 2017). This is reflected in the electrolyte concentrations 10 – 14 days 
following injection and helps to inform about future dose adjustments (Mason et al., 
2017). Electrolyte concentrations at 25 – 28 days give information on the duration of 
action (Lynn et al., 1993). Recent studies have investigated different dosing intervals to 
reduce the cost of treatment (Jaffey et al., 2017).  
1.3.7 Monitoring of Hypoadrenocorticism 
Basal cortisol and ACTH stimulation tests cannot be used to monitor dogs on treatment 
for hypoadrenocorticism as both prednisolone and fludrocortisone acetate cross-react 
with commercial cortisol assays (Krasowski et al., 2014). Dogs are primarily monitored 
by a combination of clinical signs (glucocorticoid) and electrolytes (mineralocorticoid).  
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Glucocorticoid dose decreases are warranted in patients with PU/PD, polyphagia, panting 
and a poor hair coat (i.e. clinical signs of glucocorticoid excess), whilst dose increases 
are necessary in patients that are lethargic, weak or having gastrointestinal signs (Scott-
Moncrieff, 2015, Lathan and Thompson, 2018, Farr et al., 2020). Some overlap however 
exists with lethargy and weakness potentially indicating either glucocorticoid deficiency, 
mineralocorticoid deficiency or rarely, mineralocorticoid excess.  
Mineralocorticoid supplementation (DOCP or fludrocortisone) acts to reduce potassium 
and increase sodium levels. Therefore, doses are reduced if hypernatremia or 
hypokalaemia occurs and increased with hyponatremia or hyperkalaemia. Therapy aims 
to maintain sodium and potassium levels within their normal limits (Lathan and 
Thompson, 2018, Adler et al., 2007). The sodium: potassium (Na+: K+) ratio has also been 
suggested as a clinical target for monitoring mineralocorticoid supplementation with a 
target of 27 – 32 given by the manufacturers of Zycortal® (European Medicines Agency, 
2019). As discussed in chapter 1.4.4, whilst 27 has been shown to be a sensitive marker 
for mineralocorticoid deficiency and 40 is defined as the upper limit of “normal”, 32 is a 
subjective choice with no evidence that it is any better than any other number in the 
normal range for discriminating well controlled from poorly controlled dogs (Adler et al., 
2007, Scott-Moncrieff, 2015, Nielsen et al., 2008, Roth and Tyler, 1999).  
Electrolytes are frequently measured “in-house” to allow for faster diagnoses and 
adjustments to treatment plans in a range of conditions not just hypoadrenocorticism. 
Different machines are frequently used between multiple branches of a practice (e.g. out 
of hours versus during the day) or even within a single building depending on what other 
tests required (e.g. blood gas analysis versus a full biochemistry with electrolytes).  
More advanced monitoring through repeated measurement of endogenous ACTH 
concentrations, plasma renin activity and blood pressure are discussed further elsewhere 
(Spence, 2020, Kaplan and Peterson, 1995). 
1.3.8 Prognosis 
The long-term prognosis of primary HA in dogs is good provided a prompt diagnosis is 
made and the correct treatment is instituted. Most mortality occurs around the time of 
initial presentation in acute Addisonian crisis. The median time till stabilisation is 3 
months however concurrent prednisolone administration results in faster stabilisation 
times (Roberts et al., 2016). Therefore, frequent electrolyte monitoring is essential, 
especially earlier in the course of disease. There is no link between sex, breed or age of 
diagnosis on the median survival time of 4.7 years (Kintzer and Peterson, 1997b). 
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1.4 Electrolytes 
Electrolyte abnormalities, namely hyperkalaemia and hyponatraemia, are the classic 
clinicopathological abnormalities associated with primary hypoadrenocorticism 
(Peterson et al., 1996). They occur due to mineralocorticoid deficiency resulting in the 
kidneys being unable to conserve sodium (Na+) or excrete potassium (K+) (DiBartola and 
de Morais, 2012, DiBartola, 2012) .  Hyperkalaemia occurs most commonly (74 – 96% 
of cases), followed by hyponatremia (56 – 100% of cases) and as such the Na+: K+ ratio 
is commonly evaluated and low (Lifton et al., 1996, Peterson et al., 1996, Sadek and 
Schaer, 1996, Thompson et al., 2007). On the other hand, some dogs with HA may have 
normal electrolyte concentrations including dogs with atypical HA, although not all dogs 
with normal electrolytes are atypical (Baumstark et al., 2014b). Isolated changes in 
sodium and potassium concentrations are more common in hypoadrenocorticism than 
changes in both electrolytes and up to a third of dogs may have electrolyte concentrations 
within the normal reference interval (Hughes et al., 2007).  
Although hyponatremia and hyperkalaemia predominate, hyperphosphataemia (68%), 
hypochloraemia (42%) and hypercalcaemia (32%) may also occur (Peterson et al., 1996, 
Greco, 2007, Kintzer and Peterson, 1997a, Hess, 2017). These changes may occur 
together or independently and are likely  due to altered electrolyte exchange within the 
kidneys as a result of both mineralocorticoid deficiency (chloride) and glucocorticoid 
deficiency (calcium/phosphate) (Adamantos and Boag, 2008, Gow et al., 2009). 
1.4.1 Sodium 
Sodium is the major extra extracellular cation and is a key determinant of plasma 
osmolality, tonicity and ECF volume. Changes in serum sodium often reflect changes in 
total body water stores rather than changes in total body sodium content themselves. ECF 
volume is maintained via sodium retention in response to antidiuretic hormone (ADH) 
and aldosterone acting on the kidney. The ECF sodium concentration is approximately 
140 mEq/L and ICF is around 10 mEq/L (DiBartola, 2012). 
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1.4.1.1 Normal Sodium Homeostasis 
Sodium is filtered by the glomeruli and reabsorbed by the renal tubules via active 
transport through sodium-potassium adenosine triphosphatase (Na+, K+-ATPase) pumps 
in the basolateral membranes of tubular cells. This translocates sodium from the tubular 
cell cytoplasm into the peritubular interstitium maintaining low ICF concentrations which 
in turn promotes sodium entry at the luminal surface. Around two thirds of the filtered 
sodium is reabsorbed isosmotically with water in the proximal tubules. In the early 
proximal tubules sodium is reabsorbed with co-transporters for glucose, amino acids and 
phosphate via luminal Na+-H+ antiporter.  In the late proximal tubule, sodium is 
reabsorbed primarily with chloride due to luminal Na+-H+ and Cl- - anion- antiporters 
working in parallel. Approximately a quarter of filtered sodium is reabsorbed in the loop 
of Henle, primarily in the thick ascending limb. This occurs via the Na+-H+ antiporter and 
Na+-K+-2Cl- cotransporters. Sodium and chloride are passively reabsorbed in the thin 
descending and ascending limbs. Another 5% of the filtered sodium is reabsorbed in the 
distal convoluted tubule and connecting segment. In the early distal tubule, sodium is 
reabsorbed via an Na+-Cl- cotransporters (the site of action of thiazide diuretics). The final 
~3% of filtered sodium is reabsorbed in the collecting ducts via passive diffusion through 
Na+ channels in the luminal membranes of principal cells. One of aldosterone’s effects is 
to increase the number of these channels to increase sodium reabsorption (DiBartola, 
2012).  
1.4.1.2 Hyponatraemia in Hypoadrenocorticism 
Aldosterone mediates changes in renal absorption of sodium in response to dietary intake 
by increasing the number and activity of open Na+ channels in the principal cells of the 
collecting duct. Mineralocorticoid deficiency therefore results in urinary loss of NaCl and 
depletion of ECF volume. This volume depletion is a strong non-osmotic stimulus for 
vasopressin release and impairs water excretion with a subsequent increase in potassium 
levels (DiBartola, 2012).  
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1.4.2 Chloride 
Chloride (Cl-) is the major extracellular anion and plays a key role in determining 
osmolality, tonicity and ECF volume along with sodium. It accounts for approximately 
two thirds of the anions in plasma and is the major anion filtered and reabsorbed in the 
kidney. Its concentration often parallels that of sodium to achieve electroneutrality, but 
each is independently regulated. Additionally, Cl- has a key role in renal acid base 
regulation along with bicarbonate (HCO3
-). Normal plasma chloride concentrations are 
around 110 mEq/L in dogs and 120 mEq/L in cats (de Morais, 1992).  
1.4.2.1 Normal Chloride Homeostasis 
Chloride is gained and lost through the gastrointestinal and urinary systems. Even under 
normal conditions the chloride concentration of various gastrointestinal fluids is very 
variable. Chloride is secreted along with sodium into gastric secretions and is reabsorbed 
in the jejunum. The highest concentrations of chloride are found in the ileum which is 
relatively less permeable to ion uptake than the jejunum. Chloride may be reabsorbed 
here in exchange for HCO3
-. The colon has the lowest chloride concertation as up to 90% 
of the sodium and chloride delivered to it, is reabsorbed. Chloride may also be secreted 
by the jejunum, ileum and colon (Dobbins, 1985). A loss or gain of free water or 
electrolyte rich fluids, will result in a proportional change the sodium and chloride 
concentrations. For example, severe secretory diarrhoea may result in an excessive loss 
of electrolytes via intestinal secretions combined with water retention due to the actions 
of ADH in response to hypovolaemia. This has the effect of “free water” gain. 
The kidneys also play an important role regulating plasma chloride concentration with 
chloride the second most common ion in glomerular ultrafiltrate after sodium. Most of 
the filtered chloride is reabsorbed in the renal tubules and is actively and passively linked 
to sodium reabsorption. In the proximal tubule, 50-60% of the filtered chloride is 
reabsorbed by basolateral membrane K+-Cl- cotransporters. In the loop of Henle, 
reabsorption occurs transcellularly via Na+-K+-2Cl- transporters (the site of action of loop 
diuretics) with chloride being the rate limiting step. In the distal convoluted tubule Na+-
Cl- cotransporters (thiazide sensitive) reabsorb chloride and in the collecting duct chloride 
absorption is linked to bicarbonate transport and paracellular pathways (de Morais and 
Biondo, 2012) 
INTRODUCTION  
 19 
1.4.3 Potassium 
Potassium is the major intracellular cation (along with Magnesium) and is essential for 
numerous physiological processes including enzymatic action, neuromuscular and 
cardiac conduction and routine cell function particularly in muscle and nerve cells. Most 
of the body’s potassium (60-75%) is found within muscle cells and the remainder within 
the bones. Only around 5% of potassium is in the ECF and the concentration is tightly 
regulated as small changes can be life threatening and cause marked organ dysfunction. 
The inverse relationship is seen to sodium concentrations with ECF potassium 
concentrations of around 4 mEq/L and ICF concentrations of 140 mEq/L (DiBartola and 
de Morais, 2012). 
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1.4.3.1 Normal Potassium Homeostasis 
Plasma potassium is tightly regulated as small changes can have marked effect on organ 
function and severe abnormalities are life threatening. Normal potassium levels are 
maintained through internal and external balance. External potassium balance is achieved 
by matching output via the kidneys with intake from the gastrointestinal tract and diet. 
Around 90% of potassium that is excreted is removed via the urine (kidneys) with the 
remainder via the gastrointestinal tract (colon) (Bourgoignie et al., 1985). Almost all 
ingested potassium is absorbed non-selectively in the stomach and small intestine. Uptake 
of potassium in the small intestine is passive whereas active transport in response to 
aldosterone occurs in the colon during potassium excretion. If dietary potassium is 
inadequate, renal extraction of potassium decreases and vice versa. Internal potassium 
balance is maintained by translocation of potassium between the ECF and ICF. Between 
50% and 66% of ingested potassium is excreted via the kidneys within four to six hours 
and effective translocation is required to allow the kidneys time to excrete the remainder. 
This is largely dependent on endogenous insulin and catecholamines (primarily 
epinephrine) promoting potassium uptake by cells. Insulin binds to insulin substrate 
receptor -1 which causes uptake of potassium and glucose (via GLUT-4 receptors). 
Catecholamines promote the uptake of potassium through stimulation of Na+, K+-ATPase 
pumps primarily in the liver and skeletal muscle. Tissue necrosis can cause the release of 
intracellular potassium particularly when skeletal muscle is affected. Acid-base balance 
is also important in potassium distribution with shifts of potassium in and out of cells at 
different ECF pH levels. In general acidosis causes potassium ions to move from the ICF 
to ECF (i.e. hyperkalaemia) and alkalosis causes the reverse with potassium moving into 
cells (i.e. hypokalaemia). This is most pronounced with sudden shifts in plasma pH and 
mainly appears clinically relevant with metabolic acidosis (DiBartola and de Morais, 
2012). Endotoxins can stimulate Na+, K+ ATPase pumps and cause insulin release both 
of which promote intracellular potassium shifts.   
As discussed, the kidneys are the primary regulators of potassium balance. Potassium is 
filtered at the glomerulus and then most (~70%) is reabsorbed in the proximal tubule with 
water and sodium and by paracellular diffusion. This occurs via potassium channels in 
both the luminal and basolateral membranes and by basolateral K+-Cl- cotransporters. 
Most of the remaining potassium (~20%) is reabsorbed paracellularly in the ascending 
limb of the loop of Henle via K+ channels in the luminal membrane. Some transcellular 
reabsorption of potassium occurs via luminal Na+-K+-2Cl- cotransporters and basolateral 
K+ channels and K+-Cl- cotransporters (DiBartola and de Morais, 2012).  
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The remaining (~10%) potassium is delivered to the distal nephron where potassium 
excretion or absorption may occur depending on dietary potassium intake. In the distal 
convoluted tubule luminal surface there are Na+- Cl- (thiazide sensitive) and K+-Cl- 
cotransporters which result in the secretion of potassium and reabsorption of sodium. 
There are also basolateral Na+, K+-ATPase pumps which help to maintain low 
intracellular sodium concentration and high intracellular potassium concentrations, 
further facilitating potassium secretion and sodium reabsorption. In the connecting tubule 
and collecting duct, principal cells are rich in basolateral Na+, K+-ATPase which moves 
potassium from the blood into the renal tubular cells for excretion under the control of 
aldosterone. The luminal membranes contain electrogenic sodium channels (ENaC) 
which are also stimulated by aldosterone (and the site of action of spironolactone). 
Sodium movement through this channel makes the lumen negatively charged thus 
facilitating secretion of K+ ions through luminal K+ channels. Type A (α) intercalated 
cells are found in the connecting tubule, cortical collecting duct and outer medullary 
collecting duct. They contain a range of transporters to secrete H+ ions and reabsorb K+ 
and bicarbonate (HCO3
-). Potassium is actively transported across the luminal membrane 
by H+, K+-ATPase and then diffuses down its concentration gradient through K+ channels 
in the basolateral membrane. Type B (β) intercalated cells are found only in the cortical 
collecting duct and primarily secrete HCO3
-. Potassium is able to be reabsorbed from the 
last portion of the outer and all of the inner medullary collecting duct via the paracellular 
route due to the concurrent absorption with water (DiBartola and de Morais, 2012).  
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1.4.3.2 Renal Excretion of Potassium 
Excretion of potassium in the distal nephron is mainly controlled by sodium absorption 
in the distal tubules and aldosterone. Increased extracellular potassium concentrations 
further stimulate aldosterone release and potassium excretion without sodium absorption. 
Conversely hypokalaemia (e.g. with dietary deficiency) stimulates potassium resorption. 
Renal excretion of potassium increases with the distal tubule flow rate. Higher rates (e.g. 
with fluid therapy, diuretic therapy, osmotic diuresis), enhances potassium excretion via 
increased flushing out of potassium and increased absorption of sodium via ENaC. 
Decreased distal tubule flow rates (e.g. with hypovolaemia) lead to decreased sodium 
delivery to the distal nephron and reduced potassium excretion. Increased renal tubule 
electronegativity in the collecting tubules enhances potassium excretion. This may occur 
secondary to increased sodium levels or high concentrations of negatively charged 
molecules (e.g. ketones, penicillin antibiotics, HCO3
-). Additionally, potassium excretion 
is decreased with acidemia and promoted during alkalemia. Acidosis reduces excretion 
and promotes resorption of potassium in the distal nephron due to decreased activity of 
the Na+, K+-ATPase pumps in principal cells and increased activity of the H+/K+ pump in 
the intercalated cells. Alkalaemia promotes potassium loss through intracellular shift in 
potassium in exchange for H+ ions and by stimulating ENaC (DiBartola and de Morais, 
2012).  
1.4.3.3 Hyperkalaemia in Hypoadrenocorticism 
Aldosterone release is stimulated via hyponatremia and hyperkalaemia and causes sodium 
absorption and potassium excretion from the kidney via increased activity of the 
basolateral Na+/K+ pump and ENaC, creating a negative luminal charge which promotes 
potassium excretion in exchange for sodium. Aldosterone also directly causes increased 
permeability of the luminal membrane to potassium, promoting excretion in the kidney 
and colon. Therefore, mineralocorticoid deficiency results in a gradually worsening 
hyperkalaemia due to decreased urinary excretion of potassium (DiBartola and de Morais, 
2012). 
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1.4.4 Sodium: Potassium Ratio 
The normal Na+: K+ ratio in dogs are said to lie between 27:1 and 40:1 (Scott-Moncrieff, 
2015). As a result of hyponatraemia and hyperkalaemia the Na+: K+ ratio is often low in 
dogs with primary hypoadrenocorticism (Bartges and Nielson, 1992). A Na+: K+ ratio of 
27:1 or less is found in 85-100% of cases and has been considered suggestive of 
hypoadrenocorticism whilst using 24:1 as a cut off improves detection rates with a 
specificity of up to 100% (Adler et al., 2007). However, many different conditions can 
cause electrolyte abnormalities and several studies have demonstrated the lack of 
specificity in the diagnosis of HA  (Adler et al., 2007, Nielsen et al., 2008, Roth and Tyler, 
1999, Scott-Moncrieff, 2015, Schaer et al., 2001, Seth et al., 2011). In dogs with low Na+: 
K+ ratios, HA was the cause in 13%-24% (Nielsen et al., 2008, Roth and Tyler, 1999) of 
cases depending on which cut off was used (24:1 vs 27:1). Many other diseases therefore 
can cause marked changes in the Na+: K+ ratio including urinary, gastrointestinal and 
cardiorespiratory disease as well as artefactual changes due to sample contamination with 
potassium ethylenediaminetetraacetic acid (EDTA). Additionally, it is worth noting that 
taking the upper and lower reference intervals from the reference laboratory used in this 
study, it is possible to generate a range of between 23.6 and 46.8 in dogs with “normal” 
sodium and potassium concentrations. It is therefore preferable to consider sodium and 
potassium concentrations independently in relation to their reference intervals (Nielsen et 
al., 2008). 
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1.5 Electrolyte Analysis 
Serum, plasma and whole blood concentrations of these major electrolytes can be 
measured via several different methods (Schindler et al., 2018). Flame photometry (FP) 
is the recognised reference method although it is rarely used outside of a research setting 
due to inherent impracticalities in carrying out the test. Therefore, most commercial 
reference laboratories use indirect potentiometry by an ion-selective electrode (ISE) as 
this produces results comparable to FP and is much easier and cheaper to perform. Ideally 
all electrolyte measurements would be made using an indirect ISE method however this 
is not always realistic. So called “in-house” point-of-care (POC) analysers allow for faster 
electrolyte measurements and therefore faster diagnoses and adjustments to treatment 
plans. However, inaccurate POC electrolyte measurements may lead to delayed or 
inappropriate therapy which could be clinically detrimental to patients. Dogs receiving 
treatment for hypoadrenocorticism are typically monitored by analysis of their plasma, 
serum or whole blood concentrations of sodium, potassium and the Na+: K+ ratio in 
conjunction with their clinical signs. The chloride concentration [Cl-] is usually assayed 
along with these other electrolytes on most POC analysers.  
Many different POC electrolyte analysers are commercially available for veterinary use 
and most commonly employ either direct potentiometry by an ISE, enzymatic 
spectrophotometry (ES), optical fluorescence (OF) or a colorimetric assay. In this study, 
three different methods were used measured on four different machines. Two POC 
analysers, the IDEXX Catalyst™ Dx and IDEXX VetStat® Electrolyte and Blood Gas 
Analyser were compared to a reference laboratory indirect ISE method initially using an 
Olympus AU640 and latterly the Siemens Dimension Xpand® Plus.  
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1.5.1 Electrolyte Analysis Interference  
Every electrolyte analysis method is vulnerable to interference from physiological 
abnormalities and contamination (e.g. potassium EDTA). High levels of lipid 
(hyperlipidaemia) or protein (hyperproteinaemia) may falsely decrease the electrolyte 
concentrations measured in samples. This may be important especially in dogs with other 
endocrinopathies such as hypothyroidism. Electrolytes in plasma are confined to the 
aqueous component which comprises around 93% of plasma volume and thus techniques 
such as FP and indirect ISE are affected by the excluded solid plasma components. This 
effect is usually small but is most apparent with sodium concentration as it is at a much 
higher concentration in the ECF than potassium. This can result in “pseudo-
hyponatraemia”, however it may occur with all electrolytes. Electrolyte analysis based on 
optical fluorescence or spectrophotometry as found on many POC analysers can be 
adversely affected by increased levels of bilirubin (hyperbilirubinaemia). Similarly, 
haemolysis and altered red cell stability (e.g. prolonged storage) may increase serum and 
plasma potassium concentrations through the release of intracellular potassium. Dogs 
with increased potassium on their red cells, such as Akitas, Shiba Inu, Shar-pei and some 
other Asian dog breeds and animals with marked reticulocytosis and thrombocytosis may 
cause “pseudo-hyperkalaemia” (Bernardini et al., 2009, Stockham and Scott, 2008, Scott 
et al., 2015, Schindler et al., 2018).  
1.6 Electrolyte Analysers  
1.6.1 Reference Laboratory Analysers 
1.6.1.1 Olympus AU640 
The Olympus AU640 (Beckman-Coulter Inc., Fullerton, CA, U.S.A) is a multi-
parametric wet biochemistry analyser available for routine biochemical and electrolyte 
analysis. Electrolyte analysis is based on indirect potentiometry by an ion-selective 
electrode (ISE) method for sodium, potassium and chloride determination (Blanc et al., 
2000). Indirect potentiometry involves sample dilution before analysis. This is important 
because endogenous interferents such as hyperlipidaemia or hyperproteinaemia may 
falsely decrease electrolyte concentrations as discussed above. 
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1.6.1.2 Siemens Dimension Xpand Plus 
The reference laboratory used in this study switched their biochemical and electrolyte 
analysis to the Siemens Dimension Xpand Plus (Siemens Healthcare Ltd, Surrey, UK) 
during the study period following 4 weeks of quality control to ensure comparable results. 
During this time, samples were run on both the Olympus AU640 and the Siemens 
Dimension Xpand Plus. Biochemical analysis used the same reagents and electrolyte 
analysis employed the same indirect ISE methodology on both machines. Due to the 
laboratory being unable to give an exact date for the switch between machines, these were 
treated as one indirect ISE method for the whole trial.  
1.6.2 Point-of-care Analysers 
1.6.2.1 IDEXX Catalyst™ Dx 
The IDEXX Catalyst™ Dx analyser (IDEXX Laboratories, Inc., Westbrook, Maine, 
U.S.A) is one of the most common POC analysers used in veterinary clinics. It uses “dry-
slide technology” for biochemical and electrolyte analysis. These slides are made up of 
several layers, which spreads the sample evenly, removes impurities and then reacts with 
the sample with a reagent before it is read by spectral analysis. This process involves an 
ionophore-bound fluorescent dye which reacts with the electrolytes. This produces 
fluorescence that is measured by ion-specific sensors which is converted to a numerical 
result based on intensity (fluorometry) (Idexx, 2015). The layers act as filters to try to 
minimise interference caused by physiological abnormalities but this method remains 
more susceptible to the effects of interferents than the indirect ISE method (Bernardini et 
al., 2009, Hubl et al., 1994).  
1.6.2.2 IDEXX VetStat® 
The IDEXX VetStat® Electrolyte and Blood Gas analyser (IDEXX Laboratories, Inc., 
Westbrook, Maine, U.S.A) is another commonly used POC analyser. It measures optical 
fluorescence (OF) from a blood sample analysed in a disposable single-use cassette via 
sensors called optodes. The electrolyte channels are calibrated with a buffer solution 
contained in the cassette. During measurement, light is passed through optical filters so 
that photons of a specific energy are transmitted to the sensors, causing them to emit 
fluorescence specific to each electrolytes concentration within the sample (Idexx, 2010). 
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1.7 Method Comparison Studies 
The American Society of Veterinary Clinical Pathologists (ASVCP) publishes guidelines 
for performing method comparison studies and which statistical tests should be best 
employed; the latest version of these was published after data collection for this study had 
been completed but were broadly adhered to (Arnold et al., 2019). They recommend 
calculating the correlation coefficient (r) to help determine the appropriate statistical tests 
but that this is not acceptable as a measure of agreement. For data with a narrow range, 
such as electrolytes, if r is >0.975 then standard linear regression statistics can be used to 
estimate the bias at medical decision concentrations; however, for data that vary over a 
wide range, regression statistics are typically used. If r <0.975, it may be improved by 
collecting more data points or decreasing the variance by doing replicate measurements. 
Paired t-test statistics can be used to estimate the bias as the difference between the means 
of the results by the two methods, however, they are not applicable in the presence of 
proportional error. In this situation Passing-Bablok or Deming regression analysis should 
be used. Additionally, subdivision of results into groups (below, within, or above the 
reference interval) may provide additional insights for means in ranges that are clinically 
significant. 
Bland-Altman plots should be created by plotting the difference between the two tests on 
the y-axis, and the mean (or median) of both methods on the x-axis. The line of difference 
identifies the mean bias. For tests with absent or negligible bias, results are scattered 
closely around the line of zero difference, with approximately half above and half below 
as well as a narrow range of individual differences.  
 
1.8 Aims of this study 
The aims of this study were: 
 1) to compare two commonly used point-of-care electrolyte analysers (IDEXX 
Catalyst™ Dx and VetStat®) accuracy against a reference laboratory’s results (ISE) in 
blood samples from dogs with diagnosed primary hypoadrenocorticism.  
2) to test the precision of these analysers through reproducibility studies of the results that 
were obtained and to assess the bias between analysers. 
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2 Materials &Methods 
2.1 Hypothesis 
The primary null hypothesis of this study was that the IDEXX Catalyst™ Dx and IDEXX 
VetStat® analysers would have good precision over a wide range for sodium, potassium 
and chloride concentrations. Secondary null hypotheses were that they would have high 
correlations and good agreement with results from the reference indirect ISE method and 
that any identified bias between the IDEXX Catalyst™ Dx or IDEXX VetStat® and the 
reference indirect ISE would not impact on clinical decisions. 
2.2 Study Design 
2.2.1 Experimental Design 
The experiment was designed as a prospective single-site field study performed in the UK 
at the University of Glasgow, Small Animal Hospital between October 2015 and April 
2019. Samples were initially collected from a concurrent two group, randomised, non-
masked, non-inferiority cross-over study comparing two different treatments for the 
chronic management of hypoadrenocorticism in dogs (DOCP and fludrocortisone) and 
are the subject of another MVM thesis (Spence, 2020). After the non-inferiority study had 
concluded in January 2017, additional data was gathered, and further dogs recruited to 
increase the number of test samples available to conduct a method comparison study 
which forms the basis of this MVM thesis. 
2.2.2 Sample Size Calculation 
Sample size calculations were not performed for this study however were performed for 
the initial cross-over study comparing two different treatments. The ASVCP recommends 
that method comparison studies use a minimum of 40 independent patient samples tested 
by both methods (Jensen and Kjelgaard-Hansen, 2006). Human laboratory medicine 
recommendations state that imprecision and bias are assessed based on repeated 
measurement of at least 20 samples however this recommendation has been modified to 
5 replications for veterinary POC analysers (Arnold et al., 2019). 
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2.2.3 Recording Data and Study Monitoring 
Data was recorded at the time of consultation onto paper trial documents, which were 
labelled with the animals’ hospital number, name and owner surname and visit number. 
Paperwork was stored securely between visits and at the end of the trial was manually 
entered into an electronic database. The paper copies were also digitised for review in 
future if needed. The trial monitor reviewed the electronic database to ensure accuracy. 
Owners also kept paper records at home of the medications they had administered and 
their observations of the dogs. 
2.3 Case Selection 
2.3.1 Animal Selection 
Dogs were actively recruited from surrounding private first opinion small animal 
veterinary practices. There was no restriction on breed, gender or neutering status. For 
the cross-over study, dogs had to be over 5kg in weight due to the volume of blood being 
collected. This restriction was lifted for the rest of the study as blood was only collected 
for monitoring purposes. 
2.3.2 Animal Identification 
On presentation at the hospital, each animal was given a six-digit hospital number which 
was used along with the patients’ name and owner surname, to identify all samples and 
study data.  
2.3.3 Eligibility and Inclusion Criteria 
Dogs were required to be privately owned and to have been diagnosed with 
hypoadrenocorticism using an ACTH stimulation test performed at an external reference 
laboratory, with pre and post ACTH cortisol levels <55 nmol/L. For the cross over study, 
they had to have been diagnosed at least 60 days previously and have been stable (as 
assessed by sodium and potassium concentrations within their references ranges at the 
first visit) for at least 30 days on a twice daily dose of fludrocortisone with or without 
supplemental prednisolone. This restriction was removed for the remainder of this study 
to be able to include all dogs with hypoadrenocorticism, from newly diagnosed to long 
term stable cases to ensure that the study was as representative as possible of primary care 
practice. 
Animals with concurrent diabetes mellitus, hypothyroidism or urinary incontinence were 
not excluded from the study providing those individuals had only one of these concurrent 
conditions, and the condition was stable with treatment.  
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2.3.4 Exclusion Criteria 
Dogs were excluded if they were uncooperative with study procedures (or became so 
during the study), if they were pregnant, lactating or had renal insufficiency (diagnosed 
by increased blood urea, creatinine and persistently isosthenuric urine despite intravenous 
fluid therapy). Additionally, they were excluded if they had clinical signs of primary 
hepatic failure (e.g. ascites, severe hypoalbuminemia etc), had congestive heart failure, 
were receiving immunosuppressive therapy or if they were receiving systemic steroid 
therapy other than prednisolone (for hypoadrenocorticism) or oestriol (for the treatment 
of urinary incontinence).  
2.3.5 Ethical Approval 
This study received University ethical approval (REF03a/17) and the non-inferiority trial 
was conducted under an Animal Test Certificate number ATC 10434/0002, granted to 
Dechra Limited on 7th July 2015 by the Veterinary Medicines Directorate of the UK. 
Subsequent enrolment of additional dogs with hypoadrenocorticism was performed under 
the Veterinary Surgeons Act 1966 with residual blood samples being used following 
routine monitoring.  
2.3.6 Informed Consent 
Informed consent, including a discussion of the risks of changing medication and the need 
for increased vigilance and monitoring during this time, was obtained from all owners 
before their animals were examined at the first visit. This was recorded via a signed 
consent form.  
2.4 Treatment  
2.4.1 Fludrocortisone 
Fludrocortisone acetate (Florinef, 0.1mg tablets, Bristol-Meyers Squibb Pharmaceuticals 
Ltd) was the designated control product (CP) in the non-inferiority trial and is used, off-
license, for the long-term treatment of canine hypoadrenocorticism. Due to availability 
problems during the trial, the CP was supplemented with generic Fludrocortisone acetate 
(Aspen Pharmacare Ltd) in some cases. 
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2.4.2 Desoxycortone pivalate 
DOCP (Zycortal®, 25 mg/ml, Dechra Ltd) was the designated investigational product 
(IVP) during the non-inferiority trial. It is a prolonged release formulation of DOCP in a 
microcrystalline suspension which had been recently authorised for the treatment of 
hypoadrenocorticism in dogs when the trial was started. DOCP has a licensed starting 
dose of 2.2mg/kg to be administered subcutaneously every 28 days (European Medicines 
Agency, 2019). 
2.4.3 Dose Adjustments 
Owners were strictly prohibited from making dose adjustments at home, even in the 
presence of drug-related side effects. All dose adjustments were made by either a 
Diplomate or Resident of the European College of Veterinary Internal Medicine – 
Companion Animal. The prednisolone dose was adjusted based on the presence of clinical 
signs of glucocorticoid excess (i.e. polyuria, polydipsia, polyphagia, excessive panting, 
coat changes) or deficiency (i.e. vomiting, diarrhoea, weakness). The fludrocortisone and 
DOCP doses were adjusted based on electrolyte concentrations, with hyperkalaemia or 
hyponatremia prompting a dose increase and hypokalaemia or hypernatremia resulting in 
a dose reduction. 
2.4.4 Concurrent Medications 
Dog’s receiving concurrent medications for the management of other conditions were not 
excluded from the study unless they were drugs which could interfere with the analysis 
of electrolytes and management of hypoadrenocorticism. This included diuretics and any 
systemic steroid medications other than those prescribed during the study.  
2.5 Electrolyte Monitoring 
2.5.1 Blood Sampling 
Each dog was blood sampled at baseline and at each subsequent visit via jugular 
venepuncture. Samples were collected by the attending Veterinary Surgeon or a 
Registered Veterinary Nurse under their direction. The blood sample was then 
immediately transferred into a 1.3 ml blood collection tube containing lithium-heparin.  
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2.5.2 Point-of-Care Electrolyte Measurement 
Electrolyte analysis was performed on a POC analyser within 10 minutes of blood 
sampling to allow for any changes in treatment to be made at the time of the consultation. 
Samples were preferentially run on the Catalyst analyser but when test clips were not 
available, the VetStat was used. Occasionally, at the investigator’s discretion, tests were 
performed on both POC analysers. 
Samples run on the Catalyst were centrifuged at 9000 revolutions per minute (RPM) for 
3 minutes (5433 g) and 300 µL aliquots of heparinised plasma were analysed. The VetStat 
analyser instead used a 200 µL aliquot of heparinised whole blood drawn into a 1 ml 
syringe. 
Testing materials were stored and handled as recommended by the manufacturer. Catalyst 
analyser test clips (Lyte 4 CLIP, IDEXX Laboratories, Westbrook, USA) were kept at -
20°C until immediately prior to testing. The VetStat test cassettes (Electrolyte 8 Plus, 
IDEXX Laboratories, Westbrook, USA) were kept at room temperature between 4°C and 
30°C. 
Both analysers were installed to the manufacturer’s specifications and serviced as 
recommended with daily and monthly quality control checks using quality control 
products supplied by the manufacturer (IDEXX Laboratories, 2019, IDEXX 
Laboratories, 2010). Results were shared anonymously with IDEXX’s SmartService™ 
allowing for automatic software updates and remote calibration of the analysers.  
2.5.3 Laboratory Electrolyte Measurement 
A paired sample was sent to the on-site veterinary reference laboratory (Veterinary 
Diagnostic Services, University of Glasgow). These samples were refrigerated within 4 
hours of collection and stored for a maximum of two days before analysis although the 
vast majority were tested the same day representing normal clinical practice in the 
hospital. The reference laboratory analyser utilised an indirect ISE methodology using 40 
µL of heparinised plasma diluted 1:10 (Olympus AU640 or Siemens Dimension® Xpand 
Plus). The analyser was maintained according to the manufacturers’ specifications and 
recommendations. The ISE component underwent calibration every four hours with 
internal quality controls performed daily using two levels. The reference laboratory also 
participates in the Bio-Rad International Clinical Chemistry Monthly Quality Assurance 
Scheme which includes electrolyte analysis. 
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2.6 Statistical Analysis 
All data was transferred from paper records onto a digital spreadsheet (Microsoft Excel, 
USA). Statistical analysis was performed using commercially available statistical 
software (Analyse-It Software Ltd, Version 5.40, Leeds, UK and GraphPad Prism 8, San 
Diego, USA). For all analysis, P values <0.05 were considered statistically significant. 
Individual electrolytes were analysed separately. For analysis of the Na+: K+ ratio, the 
reference laboratories reference interval of 27 to 40 was investigated first. A narrower 
Na+: K+ ratio range of 27 to 32 was also examined as this is defined as the “ideal range” 
in the public assessment report for the formulation of DOCP (Zycortal®, Dechra Ltd.) 
used in this study and licensed in Europe (European Medicines Agency, 2019). This 
narrower range is also the basis for dose adjustments of DOCP according to the data sheet. 
2.6.1 Data Analysis 
2.6.1.1 Comparison Plots 
The data was evaluated for outliers and if found these were double checked to ensure that 
they had been transcribed correctly and analysed appropriately. No replicate measures 
were performed of these more extreme outliers due to sample availability. The reference 
laboratory routinely repeated analysis of samples if they were found to be outside the 
reference interval to confirm the result. 
2.6.1.2 Normality Testing 
The data was assessed for normality by Shapiro-Wilk tests and by visual inspection of 
graphical plots. As none of the data were normally distributed, non-parametric statistical 
tests were used for all comparisons.  
2.6.1.3 Spearman’s Correlation 
The correlation between methods was measured using Spearman’s rank correlation 
coefficient (r) solely to ensure that a linear relationship was present. It was expected that 
there would be a strong correlation between analysers as they were measuring the same 
analytes, and this was found however it was <0.975 for all analytes. 
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2.6.1.4 Bland-Altman Analysis 
The agreement between methods was assessed by calculating the bias and displayed using 
Bland-Altman plots for each variable. As these differences were not normally distributed, 
95% limits of agreement (LOA) were derived based on the 2.5th and 97.5th percentiles 
and displayed around the median (Altman and Bland, 1983, Bland and Altman, 1986, 
Bland and Altman, 1999, Ludbrook, 2010). Agreement was considered good when the 
LOA were within the ASVCP recommended allowable total error (TEA) (Harr et al., 
2013). For sodium and chloride this is ± 5% of the target value and for potassium it is ± 
5% or ±10% at low concentrations. The clinical laboratory improvement amendment 
(CLIA) guidelines suggest a TEA of ± 4.0mmol/L for sodium and ± 0.5mmol/L for 
potassium so both values were considered. No CLIA guidelines are defined for chloride 
(Harr et al., 2013).   
2.6.1.5 Cohen’s Kappa 
To further assess the agreement between the IDEXX Catalyst and IDEXX VetStat and 
the reference ISE method, Cohen’s kappa coefficient (κ) statistics were calculated. 
Results were collected into three categories based on if they fell below, within or above 
the reference interval for each analyser and then compared to the ISE analyser. The 
agreement was considered poor if κ < 0.2, fair if κ = 0.21 to 0.40, moderate if κ = 0.41 to 
0.60, good if κ = 0.61 to 0.80 and very good if κ > 0.81 (Landis and Koch, 1977). 
2.6.1.6 Precision Analysis 
The inter-assay imprecisions of both the IDEXX Catalyst and IDEXX VetStat analysers 
were assessed by repeated analysis of three samples run five times consecutively on each 
analyser. Different levels of sodium, potassium and chloride were studied. This allowed 
determination of the coefficient of variation (CV), bias and intra-assay observed total 
error (TE(Obs)) for each analyte on both analysers. The TE(Obs) was defined as Bias (%) + 
2CV. The TE(Obs) was then compared to the TEA of each analyte to determine if it was 
acceptable according to the ASVCP and CLIA guidelines i.e. if TE(Obs) < TEA. (Flatland 
et al., 2014, Arnold et al., 2019).  
2.6.1.7 Passing-Bablok Regression Analysis 
All analytes showed linear correlation however their r was <0.975 so Passing-Bablok 
regression analysis was performed to further investigate analyser bias. With Passing-
Bablok regression, if the Y intercept differed significantly from 0 it was considered 
constant bias was present. Similarly, if the slope did not include 1 it was thought that there 
was proportional bias (Bablok and Passing, 1985, Jensen and Kjelgaard-Hansen, 2006). 
MATERIALS & METHODS 
 35 
2.6.1.8 Linear Regression Analysis  
Linear regression was performed to evaluate the effects of individual patients, age, sex, 
neuter status, treatment (Fludrocortisone vs DOCP) and sample number. Other 
haematological and biochemical variables were not routinely recorded, other than at the 
start and end of each phase of the non-inferiority trial, so could not be analysed. 
Potentially significant variables (P<0.2) were carried forward into a generalised mixed 
linear model with significance set as P<0.05. 
2.6.1.9 Sensitivity and Specificity  
For both the IDEXX Catalyst™ Dx and IDEXX VetStat® analysers, the sensitivity and 
specificity were calculated for detecting sodium, potassium and chloride outside their 
reference interval relative to the ISE reference method. This assumed that the ISE method 
was 100% sensitive and specific. Receiver‐operator characteristic (ROC) curve analysis 
was also performed to allow comparison of area under the curves (AUC) using the Delong 
method.  
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3 Results 
3.1 Animals 
3.1.1 Patients Enrolled 
Forty-eight dogs diagnosed with hypoadrenocorticism and treated at the Small Animal 
Hospital were enrolled into a prospective cross-sectional study between October 2015 
and April 2019. Thirty-three dogs were enrolled into the initial non-inferiority study 
(although two of these were later excluded) and a further 17 were subsequently recruited. 
3.1.2 Signalment 
The included dogs ranged in age from 0.5 to 13 years (mean 6.7 years, median 6 years). 
A range of breeds were represented including: Crossbreed (n=8), Standard Poodle (n=5), 
Cocker Spaniel (n=5), Labradoodle (n=5), Springer Spaniel (n=3), Labrador (n=3), West 
Highland White Terrier (n=2), Tibetan Terrier (n=2), Bearded Collie (n=2) and one each 
of Lhasa Apso, Jack Russel Terrier, Great Dane, Tibetan Mastiff, Toy Poodle, German 
Shorthaired Pointer, Utonagan, Husky, Cavalier King Charles Spaniel, Miniature 
Pinscher, Yorkshire Terrier, German Shepard Dog and Border Collie. They weighed 
between 2.05 kg and 69 kg (mean 22.3 kg, median 20.8 kg). Twenty-four of the dogs 
were male and 24 were female. Of these, 19 of each were neutered and five were entire. 
The signalment of the enrolled dogs are listed in Table 1. 
3.1.3 Pre-existing Conditions 
One patient was treated with glucocorticoid (dexamethasone) containing eye drops 
(Maxitrol, Alcon) for 13 days before its ACTH stimulation test. Two days prior to the 
test, prednisolone acetate drops were introduced (Pred-Forte, Allergen Ltd.) when it was 
diagnosed with chronic superficial keratitis (pannus). These drops were continued 
throughout the study period. Another patient was urinary incontinent and treated with oral 
oestradiol (Incurin, MSD Animal Health) throughout the study. Finally, another dog had 
long-standing recurrent Malassezia otitis externa and was recently treated with oral 
ketoconazole (Sporanox, Jassen-Cilag Ltd.) and amoxicillin/clavulanic acid (Synulox, 
Zoetis).  
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Table 1 – Signalment of Dogs Enrolled 
Dog 
No. 
Age 
(Yrs) 
Sex Breed Weight 
(Kg) 
Pre-
ACTH 
Cortisol 
(nmol/L) 
Post-
ACTH 
Cortisol 
(nmol/L) 
1 11 FN Crossbreed 11.1 <7 <7 
2 0.5 FE Labradoodle 14.8 <10.5 <10.5 
3 10 FN JRT 7.6 <14 <14 
4 4 MN Great Dane 69 14 72 
5 4 FN Cocker Spaniel 12.8 27 42 
6 7 FN Crossbreed 49.4 <7 <7 
7 12 MN West Highland White Terrier 10.6 18 14 
8 4 FN Labradoodle 40 <7 <7 
9 9 MN Crossbreed 27.5 <6.9 <6.9 
10 9 MN Bearded collie 21.5 <6.9 <6.9 
11 7 FN Tibetan Mastiff 30.8 30 35 
12 5 FN West Highland White Terrier 6.3 <6.5 <6.5 
13 7 MN Standard Poodle 25 <10.5 <10.5 
14 4 MN Standard Poodle 33.1 <7 <7 
15 7 MN Labrador 33.5 <7 <7 
16 8 FN Springer Spaniel 18.9 44 45 
17 11 MN Cocker Spaniel 16.1 13 9 
18 10 MN Cocker Spaniel 15.6 19.5 22.4 
19 9 MN Toy Poodle 7.6 <5.6 <5.6 
20 3 MN German Short Haired Pointer 31.3 27.6 27.6 
21 9 MN Standard Poodle 33.6 <7 <7 
22 6 FE Border Collie 18.5 34 38 
23 5 MN Tibetan Terrier 9.3 <10 <10 
24 2 MN Standard Poodle 24.7 <27.6 <27.6 
25 5 FE Utanagon 22.9 13.5 <10.5 
26 3 MN Bearded collie 20.3 <10 <10 
27 1 FE Labrador 32.8 7.2 7.92 
28 7 ME Springer Spaniel 29.4 <14 <14 
29 4 FE Crossbreed (Bearded Collie) 14.3 <14 <14 
30 6 FN Cavalier King Charles Spaniel 11.3 <7 <7 
31 3 MN Husky 40.2 <6.9 <6.9 
32 9 FN Labrador 42.1 19 21 
33 3 FN Miniature Pinscher 5.9 48 22 
34 7 FN Cocker Spaniel 9.7 21 23 
35 6 ME Labradoodle 28.8 8 <6.9 
36 12 FN Crossbreed 17.8 <6.9 <6.9 
37 11 MN Tibetan Terrier 20.8 <6.9 <6.9 
38 11 FN Crossbreed 30.9 <7 <7 
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39 5.5 ME Crossbreed 5.7 <7 <7 
40 8 ME Springer Spaniel 22 <6.9 <6.9 
41 2 ME Yorkshire Terrier 2.05 <6.9 <6.9 
42 4 MN Labradoodle 19.2 <27.6 <27.6 
43 3 FN Standard Poodle 26.1 <6.9 <6.9 
44 5 FN German Shepherd Dog 33 <6.9 <6.9 
45 13 MN Lhasa Apso 9.2 23 20 
46 6 FN Cocker Spaniel 13.9 <6.9 <6.9 
47 10 FN Labradoodle 25.1 <6.9 <6.9 
48 13 FN Crossbreed 17.8 <6.9 <6.9 
Key: MN = Male Neutered, ME= Male Entire, FN = Female Neutered, FE = Female 
Entire  
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3.1.4 Concurrent Medications 
Due to the duration of the study, several animals developed conditions requiring 
medications unrelated to their hypoadrenocorticism or its treatment by their primary care 
veterinary practices.  Five dogs were prescribed antibiotics for various conditions; three 
received amoxicillin/clavulanic acid to treat superficial pyoderma and a fourth for a 
suspected urinary tract infection. The fifth dog was prescribed clindamycin for the 
management of colitis. Two dogs were given tramadol, one for the management of 
transient hind limb lameness and the other following a minor road traffic accident 
following transition from IV methadone. This dog was also given an increased dose of 
glucocorticoids initially following the accident with IV dexamethasone. One dog was 
prescribed clotrimazole following a flare up of Malassezia otitis externa. Another dog 
was started on phenylpropanolamine (Propalin, Vetoquinol) to manage urinary 
incontinence. 
Two dogs required additional treatments possibly due to adverse effects of DOCP. One 
dog was hospitalised to treat lethargy, anorexia, hypokalaemia and hypotension with IV 
fluid therapy, potassium chloride, maropitant and spironolactone. Intravenous 
buprenorphine was also administered when it was suspected he had developed 
pancreatitis. Another dog was administered maropitant for suspected nausea following a 
single vomit, lip smacking and inappetence. None of these treatments were expected to 
affect the measurement of the dog’s electrolytes. 
3.1.5 Patients Excluded 
Two dogs were excluded from the study after recruitment due to deviations from the 
enrolment criteria. One dog’s diagnosis of hypoadrenocorticism had not been confirmed 
by an ACTH stimulation test and was based on compatible abnormal electrolyte 
concentrations and signalment (a young Bearded Collie). Another dog with persistent 
hypercholesterolaemia of 17.45 mmol/L (RI 2.0-7.0) was excluded as this may have 
effected electrolyte analysis and it was subsequently diagnosed with hypothyroidism 
during the study based on an undetectable thyroxine (T4) level and increased thyroid 
stimulation hormone (TSH) level of 3.54 ng/ml (RI 0 – 0.61). It was felt the dog was truly 
hypothyroid rather than simply having suppressed T4 due to exogenous glucocorticoid 
therapy (O'Neill et al., 2011, Torres et al., 1991, Daminet and Ferguson, 2003, Reusch et 
al., 2017). Treatment with levothyroxine was instituted and resulted in an improvement 
in the dog’s demeanour, reduction in cholesterol and normalisation of T4.  
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A third dog failed to complete the non-inferiority trial following its sudden death one 
week after enrolment, but its samples were included in this study. Post-mortem 
examination was consistent with a haemoabdomen due to a ruptured haemangiosarcoma.  
3.2 Protocol Deviations and Adverse Events 
There were two main adverse events during the trial. As mentioned, one dog died of a 
ruptured splenic haemangiosarcoma which was deemed unconnected to the trial. Another 
dog developed suspected pancreatitis following administration of DOCP although it 
recovered completely and was able to complete the trial. All samples were included in 
the final analysis.  
3.3 Study Results 
3.3.1 Study Design 
There was one significant change made to the study design during the trial which may 
have affected this study. This involved the reference laboratory changing their indirect 
ISE analyser from the Olympus AU640 to the Siemens Dimension Expand Plus. Both 
analysers were run in parallel for several weeks and found to produce comparable results 
without altering the normal reference interval for this method. The normal reference 
intervals for all three methods are listed in Table 2. 
Table 2 – Reference intervals for the reference laboratory ISE method, IDEXX Catalyst™ 
Dx and IDEXX VetStat® analysers 
Analyte Reference ISE IDEXX Catalyst IDEXX VetStat 
Na+ 
(mmol/L) 
136 – 159 144 – 160 144 – 160 
K+ (mmol/L) 3.4 – 5.8 3.5 – 5.8 3.5 – 5.8 
Na+: K+ 27 – 40 - - 
Cl- (mmol/L) 95 – 115 109 – 122 109 – 122 
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3.3.2 Number of Samples Measured 
A total of 401 paired samples were measured on one of the POC analysers and by the 
reference laboratory indirect ISE method; 329 on the IDEXX Catalyst™ Dx analyser and 
72 on the IDEXX VetStat®. Only twelve samples were analysed on both POC analysers 
but were treated independently for statistical analysis as this was such a small proportion 
of the total.  
3.3.3 Number of Samples per dog 
Some dogs had only one blood sample tested whilst others had up to 18 samples included 
at various time points, measured between both analysers. There were 45 dogs tested on 
the IDEXX Catalyst™ Dx (median of 8 samples per dog, range 1 – 14 samples) and 29 
dogs tested on the IDEXX VetStat® (median of 1 sample per dog, range 1 – 4 samples). 
A sub-analysis of the data, including only one sample per dog, found generally similar 
Spearman’s correlation coefficients to those of the whole data set. This was much closer 
for the VetStat compared to the Catalyst. When there were differences, the correlation 
was generally worse other than the sodium measured on the Catalyst and chloride 
measured on both analysers (Catalyst: Na+ = 0.67, K+ = 0.72, Na+: K+ = 0.79, Cl- = 0.78 
and VetStat: Na+ = 0.71, K+ = 0.89, Na+: K+ = 0.92, Cl- = 0.68).  
3.3.4 Sample Test Ranges 
The range over which samples were tested on both POC analysers and the reference 
indirect ISE method are listed below in Table 3.  
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Table 3 – Range over which samples were tested on the IDEXX Catalyst™ Dx, IDEXX 
VetStat® and reference ISE method. 
 
3.3.5 Linear Regression 
There was no significant association with individual dog, age, sex, treatment (DOCP and 
prednisolone vs fludrocortisone) or sample number identified. Very few parameters were 
significant at the P <0.2 threshold and all became insignificant when carried into a general 
mixed linear model.  
Catalyst 
Analyte No. of 
Samples 
ISE 
Mean 
ISE Range Catalyst 
Mean 
Catalyst 
Range 
Spearman's 
Correlation 
Na+ 329 146.9 121.1 – 159.4 152.1 123 –165 0.60 
K+ 329 4.2 2.9 – 8.2 4.4 2.9 – 8.6 0.83 
Na+: K+ 329 35.9 15.6 – 51.5 35.9 15 – 54 0.86 
Cl- 329 110.5 87 – 129.9 113.3 92 – 130 0.64 
VetStat 
Analyte No. of 
Samples 
ISE 
Mean 
ISE Range VetStat 
Mean 
VetStat 
Range 
Spearman's 
Correlation 
Na+ 72 146.1 128.1 - 159.4 156.7 129 - 164 0.69 
K+ 72 4.3 2.9 - 8.2 4.2 2.7 - 7 0.87 
Na+: K+ 72 35.5 15.6 - 51.3 38.6 18.4 - 53.7 0.89 
Cl- 72 109.6 93.1 - 118.1 116.4 102 - 123 0.67 
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3.4 IDEXX Catalyst™ 
3.4.1 Bland-Altman Analysis 
The IDEXX Catalyst™ Dx gave higher median results than the reference indirect ISE 
method for sodium and chloride concentrations but was much closer for potassium. For 
sodium, the median difference was unacceptably high at 5.0 mmol/L compared to the 
clinical target of 4.0 mmol/L. The LOA were also very wide (-6.0 to 12.3 mmol/L; -150% 
to 308%) and well outside this target. In contrast, the potassium concentration had a 
median difference of just 0.2 mmol/L achieving the CLIA clinical target difference of < 
0.5 mmol/L. However, despite the much narrower LOA (-0.9 to 0.7 mmol/L; -180% to 
140%) the range was unacceptable. Due to the smaller range over which potassium is 
measured and maintained by the body these differences may be clinically important. The 
median chloride concentration difference was acceptable at 2.5 mmol/L but the wide LOA 
(-2.5 to 9.6; -62.5% to 240%) were unacceptable if using the sodium CLIA target. This 
unreliability, especially of the sodium concentration caused a wide LOA in the Na+: K+ 
ratio results (Table 4, Figure 1). 
3.4.2 Cohen’s Kappa Agreement 
The agreement for sodium and potassium were moderate at 0.51 and 0.46 respectively. 
Chloride was only fair at 0.33. The agreement of the Na+: K+ ratio was good at 0.61 which 
remained so at 0.63 even when the narrower range of 27 to 32 was applied (Table 5, 
Figure 2). 
3.4.3 Passing-Bablok Regression Analysis 
Sodium and chloride showed constant and proportional bias whereas potassium and the 
Na+: K+ ratio did not (Table 6, Figure 3). Compared to the reference ISE method the 
Catalyst tended to under-estimate at lower sodium concentrations and over-estimate at 
higher concentrations, whilst the reverse was true of chloride concentrations. 
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3.5 IDEXX VetStat® 
3.5.1 Bland-Altman Analysis 
The IDEXX VetStat® also gave higher median results than the reference ISE method for 
all analytes other than potassium (Table 4, Figure 4). The sodium analysis had an even 
worse median difference than the Catalyst of 11.5 mmol/L with wide LOA (-0.05 to 16.9 
mmol/L; -1.25% to 423%), also failing to achieve the clinical target of 4.0 mmol/L. 
Similarly, chloride analysis was unacceptable with a median difference of 6.3 mmol/L 
and wide LOA (1.2 to 12.9 mmol/L; -30% to 323%) if using the sodium CLIA. Potassium 
analysis however performed better with an acceptable median difference of 0 mmol/L 
and narrower LOA (-1.4 to 0.6 mmol/L; -280 to 120%), although this still failed to meet 
the CLIA target of < 0.5 mmol/L difference. Given the poorer performance of the sodium 
analysis, the Na+: K+ difference was greater with wider LOA than the Catalyst. 
3.5.2 Cohen’s Kappa Agreement 
The agreement for sodium was fair at 0.24, whilst is was poor for chloride at 0.14, 
However, it was very good for potassium at 0.82. The Na+: K+ ratio was moderate at 0.60 
but when a narrower range of 27 to 32 was applied it fell to moderate at 0.48 (Table 5, 
Figure 5).  
3.5.3 Passing-Bablok Regression Analysis 
No bias was identified for potassium concentrations measured on the VetStat. A constant 
and proportional bias was identified for sodium and chloride analysis and proportional 
only for the Na+: K+ ratio (Table 6, Figure 6). Compared to the reference ISE method, the 
VetStat tended to have larger errors in chloride analysis at lower concentrations and 
smaller errors at higher concentrations whilst the opposite was true for sodium. 
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Table 4 – Summary of Bland-Altman analysis of the IDEXX Catalyst™ Dx and IDEXX 
VetStat® analysers compared to the reference ISE method. 
Catalyst 
Analyte Median 
Difference + 95% 
CI 
Lower LOA + 
95% CI 
Upper LOA + 
95% CI 
r coefficient 
Na+ 5.0 (4.6 to 5.4) -6.0 (-2.7 to -0.9) 12.3 (11.6 to 
15.0) 
0.81 
K+ 0.2 (0.1 to 0.2) -0.9 (-1.2 to -0.6) 0.7 (0.6 to 0.8) 0.90 
Na+: K+ -0.4 (-0.6 to 0.0) -4.6 (-5.7 to -3.9) 8.0 (6.0 to 9.5) 0.88 
Cl- 2.5 (2.0 to 3.0) -2.5 (-3.3 to -1.9) 9.6 (8.8 to 10.8) 0.83 
VetStat 
Analyte Median Difference 
+ 95% CI 
Lower LOA  Upper LOA  r coefficient 
Na+ 11.5 (10.6 to 12.1) 
 
-0.05 16.9 0.84 
K+ 0 (0 to 0) 
 
-1.4 0.6 0.89 
Na+: K+ 2.6 (2.3 to 3.2) 
 
-4.0 10.4 0.91 
Cl- 6.3 (5.7 to 6.7) 
 
1.2 12.9 0.80 
Key: CI = Confidence Interval, N.B. CI could not be calculated for the IDEXX VetStat 
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Figure 1 – Bland-Altman Plots for Sodium, Potassium, Chloride and Na+: K+ ratios on the IDEXX 
Catalyst™ Dx. The dotted lines represent the upper and lower limits of agreement (LOA) and the 
dashed line represents the median difference. 
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 Table 5 – Summary of Cohen's Kappa coefficient analysis of the IDEXX Catalyst ™ Dx 
and IDEXX VetStat ® analysers compared to the reference ISE method. 
 
 
 
 
 
 
 
Analyte Kappa 
Coefficient 
(κ) 
95% Confidence Interval Standard Error 
Catalyst 
Na+ 0.51 0.33 to 0.69 0.09 
K+ 0.46 0.29 to 0.63 0.09 
Na+: K+ 
(27 – 40) 
0.61 0.52 to 0.71 0.05 
Na+: K+ 
(27 – 32) 
0.63 0.54 to 0.72 0.05 
Cl- 0.33 0.19 to 0.47 0.07 
VetStat 
Na+ 0.24 0.03 to 0.45 0.10 
K+ 0.82 0.63 to 1.0 0.10 
Na+: K+ 
(27 – 40) 
0.60 0.42 to 0.78 0.09 
Na+: K+ 
(27 – 32) 
0.48 0.26 to 0.70 0.11 
Cl- 0.14 -0.17 to 0.45 0.16 
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Figure 2 – Cohen’s Kappa coefficient analysis of the IDEXX Catalyst™ Dx compared to the reference 
ISE method. 
RESULTS 
 52 
 
  
RESULTS 
 53 
RESULTS 
 54 
  Figure 3 – Passing-Bablok regression analysis of the IDEXX Catalyst™ Dx compared to the reference ISE 
method.  
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Figure 4 – Bland-Altman Plots for Sodium, Potassium, Chloride and Na+: K+ ratios on the 
IDEXX VetStat®. The dotted lines represent the upper and lower limits of agreement (LOA) 
and the dashed line represents the median difference.  
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  Figure 5 – Cohen’s Kappa coefficient analysis of the IDEXX VetStat® compared to the reference 
ISE method. 
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  Figure 6 – Passing-Bablok regression analysis of the IDEXX VetStat® compared to the reference ISE 
method. 
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Table 6 – Summary of Passing-Bablok regression analysis of the IDEXX Catalyst™ Dx 
and IDEXX VetStat ® analysers compared to the reference ISE method.  
 
Key: CI = Confidence Interval.  
Constant bias was present if the 95% CI for the Y intercept of the regression line did not 
include 0.  
Proportional bias was present if the 95% CI for the slope of the regression line did not 
include 1 
 
 
  
Catalyst 
 y intercept Slope 
Analyte Estimate 95% CI Constant 
Bias 
Estimate 95% CI Proportional 
Bias 
Na+ -35.74 -57.86 to -
17.32 
Yes 1.28 1.15 to 
1.43 
Yes 
K+ 0.07 -0.325 to 0.2 No 1.03 1 to 1.13 No 
Na+: K+ -0.37 -2.0 to 1.68 No 1 0.94 to 
1.05 
No 
Cl- 14.36 6.03 to 22.38 Yes 0.89 0.82 to 
0.97 
Yes 
VetStat 
 y intercept Slope 
Analyte Estimate 95% CI Constant 
Bias 
Estimate 95% CI Proportional 
Bias 
Na+ -20.51 -55.64 to 11.64 Yes 1.22 1 to 1.46 Yes 
K+ 0 -0.24 to 1.09 No 1 1 to 1.06 No 
Na+: K+ -1.5 -5.13 to 1.3 No 1.12 1.04 to 
1.23 
Yes 
Cl- 48.03 32 to 63 Yes 0.63 0.49 to 
0.77 
Yes 
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3.6 Total Observed Error Analysis 
Both the IDEXX Catalyst and VetStat analysers did not meet the precision targets for 
sodium, potassium and chloride with TE(Obs) higher than the TEA in all cases other than 
the chloride measured on the VetStat which was just acceptable (Table 7). The coefficient 
of variation (CV) for all analytes was relatively small on both analysers so this failure 
was mainly due to the large bias that was present in both machines.  
The clinical relevance of this disagreement between methods was investigated by 
assessing how often the POC analysers produced discordant results (i.e. results which fell 
outside their normal reference interval on a POC analyser when the ISE method found 
them to be “normal” and within the reference interval or vice versa). For the Na+: K+ ratio, 
the narrower range of 27 to 32 was used as this is recommended for the adjustment of 
Zycortal® (DOCP) doses.   
With the Catalyst analyser, discordant results were produced in 21 cases (6%) for sodium 
concentrations, 27 cases (8%) for potassium concentrations, 46 cases (14%) for chloride 
concentrations and 47 cases (14%) for the Na+: K+ ratio.  
The VetStat analyser meanwhile produced results which disagreed with the ISE method 
in 19 cases (26%) for sodium concentrations, 3 cases (4%) for potassium concentrations, 
9 cases (13%) for chloride concentrations and 14 cases (19%) for the Na+: K+ ratio. 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 71 
Table 7 – Summary of the intra-assay coefficient of variation, bias and observed total 
error of the IDEXX Catalyst ™Dx and IDEXX VetStat ® analysers. 
 Catalyst VetStat 
Analyte TEA CV% Bias % TE(Obs) % CV% Bias % TE(Obs) % 
Na+ 5% 1.3 
(1.1 to 
1.6) 
3.5 
(-2.3 to 
5.3) 
6.1 
(4.7 to 
7.6) 
0.6 
(0.3 to 
0.8) 
7.6 
(-10.6 to -
4.2) 
8.7 
(4.8 to 
11.7) 
K+ 5% 2.5 
(2.3 to 
2.7) 
9.0 
(-17.0 to -
3.3) 
14.0 
(8.4 to 
21.6) 
1.2 
(1.0 to 
1.6)  
4.7 
(-7.7 to 
1.7) 
7.2 
(3.7 to 
11.0) 
Cl- 5% 1.8 
(1.0 to 
2.9) 
3.5 
(-5.2 to 
0.8) 
7.2 
(2.9 to 
10.9) 
0.5 
(0.4 to 
0.5) 
4.2 
(-7.2 to -
1.3) 
5.0 
(2.2 to 
8.0) 
 
Key: CV= Coefficient of Variation 
TE(Obs)= Observed Total Error 
3.7 Sensitivity and Specificity 
The sensitivity and specificity of both POC analysers was investigated relative to their 
ability to detect electrolyte concentrations that fell outside their respective reference 
intervals compared to that of the reference laboratory indirect ISE method (Table 8). The 
Catalyst analyser was relatively poorly sensitive detecting hypernatremia, 
hyperchloremia and hypokalaemia but had good specificity. The poor sensitivity was 
partly because no samples had increased sodium concentrations and very few had 
increased chloride levels however the poor sensitivity for hypokalaemia is more 
concerning clinically.  
The VetStat analyser had poor sensitivity for detecting low sodium and high chloride 
concentrations. Again, this was likely due to low sample numbers with these changes 
reducing the confidence intervals. The specificity for detecting high sodium 
concentrations was poorer than those of other electrolyte abnormalities on this analyser. 
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Table 8 – Summary of the sensitivity and specificity of the IDEXX Catalyst ™ Dx and 
IDEXX VetStat® analysers with 95% Confidence Intervals. 
 Catalyst Vetstat 
ISE Analyte Sensitivity 
 
Specificity AUC Sensitivity Specificity AUC 
Hypernatremia 
(>159 mmol/L) 
0.00  
(0.00 to 
0.79) 
0.96 
(0.94 to 
0.98) 
0.52 
 
1.00  
(0.34 to 
1.00) 
0.76  
(0.65 to 
0.85) 
0.88 
(0.83 
to 
0.93) 
Hyponatremia 
(<136 mmol/L) 
0.92  
(0.67 to 
0.99) 
0.98 
(0.96 to 
0.99) 
0.95 
(0.88 
to 
1.03) 
0.75  
(0.30 to 
0.95) 
0.99  
(0.92 to 
1.00) 
0.87 
(0.62 
to 
1.11) 
Hyperkalaemia 
(>5.8 mmol/L) 
1.00 
 (0.61 to 
1.00) 
0.98 
(0.96 to 
0.99) 
0.99 
(0.98 
to 1.0) 
1.00  
(0.34 to 
1.00) 
1.00  
(0.95 to 
1.00) 
1.0 
 
Hypokalaemia 
(<3.4 mmol/L) 
0.33  
(0.17 to 
0.55) 
0.98 
(0.96 to 
0.99) 
0.66 
(0.55 
to 
0.76) 
1.00  
(0.61 to 
1.00) 
0.96  
(0.88 to 
0.98) 
0.98 
(0.95 
to 1.0) 
Hyperchloremia 
(>115 mmol/L)  
0.23  
(0.12 to 
0.39) 
1.00  
(0.99 to 
1.00) 
0.61 
(0.54 
to 
0.69) 
0.00  
(0.00 to 
0.39) 
0.99  
(0.92 to 
1.00) 
0.51 
(0.49 
to 
0.52) 
Hypochloraemia 
(<95 mmol/L) 
1.00  
(0.61 to 
1.00) 
0.94  
(0.91 to 
0.96) 
0.97 
(0.96 
to 
0.98) 
1.00  
(0.21 to 
1.00) 
0.96  
(0.88 to 
0.99) 
0.98 
 
Key: AUC = Area Under Curve 
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4 Discussion 
4.1 Study Design 
This study achieved the ASVCP recommendation for method comparison studies as more 
than 40 paired samples were tested on both POC analysers. However, not all these 
samples were truly independent as multiple dogs were tested numerous times. This was 
not a problem for the IDEXX Catalyst as 45 different dogs were included however the 
IDEXX VetStat only achieved 29 individual dogs. 
The precision analysis also reached the ASVCP recommendation of five replications for 
intra-assay (within run) variation however this could have been more robust by also being 
performed over five consecutive days to ascertain any inter-assay (between run) changes.   
4.2 Study Results 
4.2.1 Study Population 
The study population was very diverse with a range of different ages, breeds and therefore 
weights of dogs and equal numbers of each sex. Some dogs presented were newly 
diagnosed with hypoadrenocorticism and had just been transitioned onto long term 
treatment whilst others had been stable on treatment for many months or years. This 
makes it representative of dogs with hypoadrenocorticism seen in clinical practice. There 
was no effect of individual dogs, age, breed, sex, nor what medications it was receiving. 
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4.2.2 Point-of-care Analyser Performance 
The concentrations of sodium, potassium and chloride measured by the Catalyst and 
VetStat analysers, as well as the calculated Na+: K+ ratios, are not interchangeable with 
those from a reference laboratory analyser using an indirect ISE method. Cohen’s Kappa 
coefficient analysis was performed to assess the agreement between the POC analysers 
using analyser specific reference intervals and found that chloride κ values were only fair 
or poor whilst sodium analysis performed only slightly better, being classified as 
moderate or fair. Potassium analysis on the other hand was more reliable and classified 
as very good on the VetStat analyser. Some variation was expected given the different 
methodology involved with each analyser; however, the magnitude especially of the 
difference in sodium concentrations measured, is clinically significant in dogs treated for 
hypoadrenocorticism. Electrolyte derangements are common with many disease 
processes and it is very important that POC analysers accurately measure electrolytes 
across a range of concentrations. 
Hypoadrenocorticism is often diagnosed in dogs with low Na+: K+ ratios however low 
ratios are also frequently found in many other disease conditions, especially those 
affecting the urogenital, cardiorespiratory and gastrointestinal systems (Nielsen et al., 
2008). The data sheet for Zycotal® (25mg/ml, Dechra Ltd.), the formulation of DOCP 
licensed to treat dogs with hypoadrenocorticism in the European Union (European 
Medicines Agency, 2019), relies on the use of Na+: K+ ratios for dose adjustments. The 
Na+: K+ ratios produced on these POC analysers were often different when compared to 
those from the reference laboratory indirect ISE method but not consistently (i.e. 
sometimes they were higher and sometimes lower). This study found that there were 
many instances in which treatment decisions would have been different depending on 
which analyser was used. This was also true when the sodium and potassium 
concentrations themselves were examined in relation to the analysers reference intervals. 
This study found that in up to 14% of Catalyst samples and 26% of VetStat samples, 
different and potentially deleterious treatment decisions could be made which is clinically 
relevant. In this study that would have meant under or overdosing dogs with DOCP, but 
these results are likely also true of dogs with conditions other than hypoadrenocorticism. 
Previous studies have shown other POC analysers, utilising a different methodology 
(direct ISE),also have poor agreement and correlation when measuring electrolytes (West 
et al., 2014, Uyanik et al., 2015).  
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In a survey of veterinary practices, POC analysers manufactured by IDEXX accounted 
for 85% of all in practice analysers and more than two thirds (71%) of respondents 
reported that they used the reference intervals supplied by the manufacturer without 
further adjustment or assessment (Bell et al., 2014). The ASVCP recommend that 
reference intervals supplied by instrument manufacturers are validated to ensure that they 
are suitable for the population which they will be testing (Flatland et al., 2013). It is 
recognised that using an instrument of the same or similar analytical methodology may 
provide different results due to differences in patient population and operator and site-
specific differences. It is recommended that validation be pursued using at least 20 patient 
samples as detailed in the ASVCP reference interval guidelines  (Friedrichs et al., 2012). 
This lack of instrument specific reference intervals for the Catalyst and VetStat analysers 
likely accounts for their poor performance in this study. 
The results of this study can, strictly, only be directly applied to the individual IDEXX 
Catalyst™ Dx and VetStat® analysers which were tested in the Small Animal Hospital, 
University of Glasgow and do not necessarily apply to all analysers from this 
manufacturer, those of the same model or of other analysers utilising these methods from 
different manufacturers. However, it is likely that the general findings are applicable and 
highlight that caution should be applied when interpreting electrolyte concentrations from 
POC analysers. A previous study has documented variations in the diagnostic 
performance between analysers of the same model as one of those used in this study 
(IDEXX Catalyst™ Dx) as well as many others not tested (Rishniw et al., 2012). 
Therefore, each individual analyser’s performance should be evaluated and ideally the 
same analyser be used for all repeated analysis. This may be difficult however when 
model specific reference intervals are produced by the manufacturer as with the IDEXX 
Catalyst™ Dx (IDEXX Laboratories, 2015) and IDEXX VetStat® (IDEXX Laboratories, 
2010).    
4.2.3 Precision Analysis 
Both POC analysers provided unacceptable electrolyte concentration results on repeated 
analysis according to the ASCVP TEA limits. No investigation of inter-assay variation 
was performed so it is possible that significant CV and bias also existed between runs. 
Both POC analysers had regular quality control tests performed and it is likely that this 
was more often than would be performed in a first opinion practice given the study’s 
setting in a busy teaching hospital. 
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4.3 Limitations 
4.3.1 Case Selection 
Only dogs with hypoadrenocorticism were included in this study. Whilst it is felt unlikely, 
there could be an unidentified substance (i.e. matrix effect) in dogs with 
hypoadrenocorticism which is not present in healthy dogs or dogs with other disease 
conditions which could have interfered with electrolyte analysis. Some caution should 
therefore be applied when extrapolating the results from this study to other canine 
diseases and especially to conditions in other species. However, this is representative of 
clinical practice and is hopefully mitigated to a degree by excluding dog’s with multiple 
diseases. Additionally, some dogs were included multiple times whilst others were 
included only once on each analyser. Some dogs may have had some unknown quality 
which affected analysis by one method and not another; however, this was felt to be 
unlikely and would not be accounted for in clinical practice. Linear regression did not 
identify any effect of individual dog, age, sex, treatment (DOCP and prednisolone vs 
fludrocortisone) and sample number. 
4.3.2 Cortisol Assays 
The European Society of Veterinary Endocrinology runs the voluntary European 
Veterinary Endocrine Quality Assurance Scheme (EVE-QAS). This aims to promote high 
quality and accurate hormonal laboratory testing which is consistent between 
laboratories. At the last test release, cortisol testing had a CV of 13% between the 
laboratories involved (European Society of Veterinary Endocrinology, 2019). 
Laboratories which have signed up to such a scheme are more likely to engage in regular 
quality assurance and use validated methods. Most of the dogs diagnosed with 
hypoadrenocorticism in this study were diagnosed in first opinion practise. Therefore, 
different external laboratories were used potentially employing different cortisol assays 
run on different analysers with different reference intervals compared to the Veterinary 
Diagnostic Service used by the Small Animal Hospital which is a member of the EVE-
QAS. 
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4.3.3 Sample Ranges 
Given the population of dogs which were studied, there were no samples with a sodium 
concentration which fell above the upper reference interval of the reference indirect ISE 
method. It is therefore possible that different biases may exist in this untested zone which 
were not identified in this study. This also limited the sensitivity and specificity analysis 
of these analysers. Hypernatremia is less frequently encountered in clinical veterinary 
practice than hyponatremia with a 5.7% incidence rate versus 25.5% for hyponatremia 
(Ueda et al., 2015). Future studies would need to examine confirmed cases of 
hypernatremia compared to normal controls.    
4.3.4 Sample Numbers 
Fewer samples were run on the IDEXX VetStat® compared to the IDEXX Catalyst™ 
Dx. Ideally the same number of samples would have been run on both machines with 
samples run in triplicate i.e. on both IDEXX analysers and at the reference laboratory. 
This was not possible as it would have required collecting more blood than was clinically 
necessary and funding was not available for this additional testing. 
4.3.5 Treatments 
 The dogs included in this study were either treated with DOCP and prednisolone or with 
fludrocortisone. Some dogs were treated with both treatments at different time points. 
Ideally only one treatment regime would have been used throughout to remove this 
confounding factor however linear regression did not identify an effect of treatment.  
4.3.6 Study Duration 
This study took place over a long period of time and some change in analyser performance 
may have been expected. This is a recognised problem that potentiometry based methods 
can suffer from degradation of the ISE itself, eventually requiring replacement. In 
contrast, the methods used in POC analysers, generally do not require routine periodic 
replacement of equipment. However, this more closely represents clinical practice as 
most veterinary practices keep their POC electrolyte analyser for many years and often 
service them themselves rather than by the manufacturer (Bell et al., 2014). There was no 
evidence of change over time from our data which may have been due to the regular 
servicing and quality control procedures within our hospital.  
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4.3.7 Change in Laboratory Analyser 
The change in analyser from the Olympus AU640 to the Siemens Dimension Xpand Plus 
was unfortunate but unavoidable during this study. In a clinical setting, a reference 
laboratory changing their analyser would go unnoticed by the submitting veterinary 
surgeon and it was ensured that the two analysers were producing comparable results 
before the switch was made. Additionally, analysis of the samples from the first and last 
three dogs tested on the reference analyser (i.e. the Olympus AU640 at the start compared 
to the Siemens Dimension Xpand Plus at the end), showed no significant change during 
the study period. This study may have been more robust if this change had not been made 
but the change may have increased the relevance of the study being more comparable to 
clinical practice.  
4.3.8 Other Clinical Pathology Parameters 
Routine biochemistry and haematology testing were not performed at the same time as 
each electrolyte sample during this study and it is possible that some of the dogs may 
have had altered PCV, protein or lipid levels during some visits. These physiological 
abnormalities may have impacted electrolyte analysis and varied between samples. This 
represents normal clinical practice and should have been accounted for to a degree by 
using paired samples. However, data from the 30 of the dogs included in the clinical trial 
that ran alongside this study does not suggest this was a problem. This trial compared 
dogs treated with DOCP and prednisolone to those treated with fludrocortisone alone. On 
haematology, it found an increase in neutrophil count in dogs treated with DOCP and 
prednisolone, likely due to exogenous glucocorticoids causing a “stress leukogram”. On 
biochemistry, the urea and creatinine levels were lower in dogs treated with DOCP and 
prednisolone(Spence, 2020). 
4.3.9 Samples Tested 
The IDEXX VetStat® analyser tests were performed on heparinised whole blood rather 
than plasma as with the IDEXX Catalyst™ Dx and laboratory indirect ISE method. It is 
possible that this caused a difference in the analysis and future studies should look at any 
difference between electrolytes analysed in whole blood, plasma and serum on this 
analyser. It is well documented that whole blood and plasma samples invariably contain 
slightly lower potassium levels (0.1 to 0.7 mmol/L) compared to serum depending on 
platelet count, however the effect of whole blood versus plasma is less clear. Most 
reference laboratory intervals for serum potassium are 0.2 to 0.5 mmol/L higher than 
those for plasma (Schindler et al., 2018). 
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4.4 Future Studies 
Further work is needed to assess the IDEXX Catalyst™ Dx and IDEXX VetStat® 
analysers between day variation. Future studies should also aim to assess electrolyte 
analysis in a range of other medical conditions, over a wider range of sodium, potassium, 
chloride and Na+: K+ ratios. Additionally, different POC analysers should be investigated 
especially those using different methodologies (e.g. direct ISE). 
4.5 Conclusion 
This study demonstrates that there are inherent differences between the electrolyte 
concentrations measured by the IDEXX Catalyst™ Dx and IDEXX VetStat® analysers 
and a reference laboratory using an indirect ISE method in dogs with 
hypoadrenocorticism. Therefore, the null hypotheses were rejected.   
4.6 Clinical Implications 
As a result, it is important that clinicians do not to rely on the electrolyte values produced 
by these analysers at the expense of other clinical findings. It is suggested that the same 
analyser be used for all dose adjustments and repeated electrolyte analysis, with attention 
paid to the individual reference interval for that machine. Additionally, clinicians should 
take steps to ascertain how their electrolyte analyser compares to their reference analyser 
in cases where comparisons are made.    
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